It was never claimed that it was a cure for several decades of degenerative brain disease caused by accumulation of amyloid plaque.
As far as the Cochrane Reviews go, these are mostly corporate funded studies designed to fail, thereby attempting to discredit natural therapies which are the source of most synthetic medical molecules.
So, we find that this corporate post denounces its effects but a really old German companyfinds that it definitely does work as it has for a long time for many people.
They never give up. The corporate hounds want you to depend on their non-working artificial molecules to make them rich by discrediting what cheap God given natural cures exist.
Wednesday, December 30, 2009
Sunday, December 27, 2009
Well if it isn't Vitamin C again. Inducible Pluripotent Stem Cells Need It.
The race towards rejuvenating the body by literally rebuilding it continues on in the milieu of stem cells. There is still quite a large misunderstanding of what one is, and actually there isn't one, there are many from many sources. Right now, your body is churning out cells from your own stem cells in your bone marrow, muscles, organs, everywhere. The problem is to keep this process going in an organized way well into old age. Too little, and you get the familiar loss of function of old age. Too much, and you get things like cancer.
Another promising new field of work is taking any cell from the adult body which contains the chromosomal makeup of the entire body except in rare chimeric cases, and taking it back to a primordial source cell. This inducible pluripotent stem cell (IPSC) can be tweaked to become an entirely different cell, offering hope for organ and tissue regeneration and repair or even rebuilding entire systems in the future.
Some grouchy old persons will be annoyed to read that you can't do it efficiently without Vitamin C.
Another promising new field of work is taking any cell from the adult body which contains the chromosomal makeup of the entire body except in rare chimeric cases, and taking it back to a primordial source cell. This inducible pluripotent stem cell (IPSC) can be tweaked to become an entirely different cell, offering hope for organ and tissue regeneration and repair or even rebuilding entire systems in the future.
Some grouchy old persons will be annoyed to read that you can't do it efficiently without Vitamin C.
Wednesday, November 18, 2009
Iodine Deficiency and Breast Cancer Association
As with all multifactorial diseases, this is not the only cause, but the fact that some cases respond to simple seaweed or iodine supplementation is profound and important.
Breast Cancer Iodine Therapy
Breast Cancer Iodine Therapy
Tuesday, November 17, 2009
Good to Know! Solasodine Glycoside (BEC5) From Eggplant Cures Skin Cancer
Copied and pasted from Natural News:
Eggplant Cancer Cure
"Eggplant Cures Skin Cancer
by Melanie Grimes, citizen journalist
See all articles by this author
Email this author
(NaturalNews) An ingredient in common eggplant has been shown to cure cancer. The eggplant extract is a phytochemical called solasodine glycoside, or BEC5. Dr. Bill E. Cham discovered it, after hearing of a folk medicine cure from Australian farmers. They told him of eye cancers cured in cattle after application of a poultice made from the fruit of a weed called Devil's Apple, known in Latin as Solanum linnaeanum. This plant is part of the Solanacea family, which includes other common vegetables such as tomato and eggplant.
BEC5 works by bonding to a receptor on the surface of the cancer cell. After the cell digests the eggplant extract, it causes the cell to rupture. The cancer cell is destroyed and its contents are then reabsorbed by the body.
BEC5 has been proven effective in treating over 80,000 cases of skin cancer, preventing surgery. The types of cancer treated by eggplant are both invasive and non-invasive non-melanoma skin cancers. In every case the cancers went into remission and did not return. Australians have been curing their skin cancers using these phytochemicals for decades.
BEC5 acts by killing cancer cells without harming any other healthy cells in the human body. BEC5 can also be used to treat actinic keratose, the precursor to cancer, as well as age or sunspots on the skin.
Actinic keratoses are a possible predictor of skin cancer. These red patches caused by sun exposure are made of abnormal cells that can mutate into malignant cells in the basal, or lower layers of the skin. Squamous cell carcinomas are another common form of skin cancer, and one which causes nearly two thousands deaths annually. This wart-type growth has irregular borders and can also be treated with the eggplant extract.
Used as a cream for over twenty-five years in clinical trials in both Australia and the United Kingdom, BEC5 had success rate of over 78% when applied for eight weeks. Used for 12 weeks, the cream had a 100% success rate in removing cancers, none of which returned for the following five years.
Over one million new cases of non-melanoma skin cancers are diagnosed each year in the United States alone. Skin cancer is now the most common illness in men over the age of 50. It is even more common than lung, prostate or colon cancer. Incidences are so common that one out of three Caucasians are now expected to develop skin cancer at some point in their lives. With this simple, natural remedy, many surgeries might be prevented and health restored."
Eggplant Cancer Cure
"Eggplant Cures Skin Cancer
by Melanie Grimes, citizen journalist
See all articles by this author
Email this author
(NaturalNews) An ingredient in common eggplant has been shown to cure cancer. The eggplant extract is a phytochemical called solasodine glycoside, or BEC5. Dr. Bill E. Cham discovered it, after hearing of a folk medicine cure from Australian farmers. They told him of eye cancers cured in cattle after application of a poultice made from the fruit of a weed called Devil's Apple, known in Latin as Solanum linnaeanum. This plant is part of the Solanacea family, which includes other common vegetables such as tomato and eggplant.
BEC5 works by bonding to a receptor on the surface of the cancer cell. After the cell digests the eggplant extract, it causes the cell to rupture. The cancer cell is destroyed and its contents are then reabsorbed by the body.
BEC5 has been proven effective in treating over 80,000 cases of skin cancer, preventing surgery. The types of cancer treated by eggplant are both invasive and non-invasive non-melanoma skin cancers. In every case the cancers went into remission and did not return. Australians have been curing their skin cancers using these phytochemicals for decades.
BEC5 acts by killing cancer cells without harming any other healthy cells in the human body. BEC5 can also be used to treat actinic keratose, the precursor to cancer, as well as age or sunspots on the skin.
Actinic keratoses are a possible predictor of skin cancer. These red patches caused by sun exposure are made of abnormal cells that can mutate into malignant cells in the basal, or lower layers of the skin. Squamous cell carcinomas are another common form of skin cancer, and one which causes nearly two thousands deaths annually. This wart-type growth has irregular borders and can also be treated with the eggplant extract.
Used as a cream for over twenty-five years in clinical trials in both Australia and the United Kingdom, BEC5 had success rate of over 78% when applied for eight weeks. Used for 12 weeks, the cream had a 100% success rate in removing cancers, none of which returned for the following five years.
Over one million new cases of non-melanoma skin cancers are diagnosed each year in the United States alone. Skin cancer is now the most common illness in men over the age of 50. It is even more common than lung, prostate or colon cancer. Incidences are so common that one out of three Caucasians are now expected to develop skin cancer at some point in their lives. With this simple, natural remedy, many surgeries might be prevented and health restored."
Tuesday, November 3, 2009
Natural Insulinomimetics and AMPK Activators (Metformin Alternatives)
Insulin serves to tell cells with a pronounced phospholipid bilayer through which glucose cannot diffuse to produce GLUT receptors which actively take in glucose to fuel the cells processes. In diabetes mellitus, there are several things that compound over time to produce the end-stage disease after many years. Generally, diabetes type 2 is diet induced over many years through excessive sugar in the diet which constantly stimulates the pancreas to secrete insulin. Over time, the insulin receptors literally disappear and become numb in a phenomenon called "desensitization." Then, no matter how much insulin is present, the glucose builds up in the bloodstream because the cells no longer listen to the insulin signal. This excess glucose is toxic, as it autocatalyzes into open-ring and chain-form reactive carbonyls or "Sugar Free Radicals." These SFR attach themselves to any L-Arginine and L-Lysine residues they can find in the proteins of the body, whether it be in the artery, eye, blood cell, or kidney. Yet, this entire process is hypothetically and theoretically reversible both through artificial therapies, and most importantly, natural ones. It is now known that in Diabetes Type 1, Leptin overexpression rescues this defect. Therefore, there is continual hope for those with both diabetes 2 and diabetes 1, that it isn't the end of the world, and "it's just one of those things people get sometimes."
1: Cazarolli LH, Folador P, Moresco HH, Brighente IM, Pizzolatti MG, Silva FR.
Stimulatory effect of apigenin-6-C-beta-L-fucopyranoside on insulin secretion and glycogen synthesis. Eur J Med Chem. 2009 Nov;44(11):4668-73. Epub 2009 Jul 9. PubMed PMID: 19625113.
2: Montagut G, Onnockx S, Vaqué M, Bladé C, Blay M, Fernández-Larrea J, Pujadas
G, Salvadó MJ, Arola L, Pirson I, Ardévol A, Pinent M. Oligomers of grape-seed procyanidin extract activate the insulin receptor and key targets of the insulin signaling pathway differently from insulin. J Nutr Biochem. 2009 May 13. [Epub ahead of print] PubMed PMID: 19443198.
3: Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14070-5. Epub 2008 Sep 8. PubMed PMID: 18779578; PubMed Central PMCID:
PMC2544580.
4: Aydemir-Koksoy A, Turan B. Selenium inhibits proliferation signaling and restores sodium/potassium pump function of diabetic rat aorta. Biol Trace Elem Res. 2008 Winter;126(1-3):237-45. Epub 2008 Aug 14. PubMed PMID: 18704274.
5: Nishide M, Yoshikawa Y, Yoshikawa EU, Matsumoto K, Sakurai H, Kajiwara NM.
Insulinomimetic Zn(II) complexes as evaluated by both glucose-uptake activity and inhibition of free fatty acids release in isolated rat adipocytes. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1181-3. PubMed PMID: 18670123.
6: Zanatta L, Rosso A, Folador P, Figueiredo MS, Pizzolatti MG, Leite LD, Silva
FR. Insulinomimetic effect of kaempferol 3-neohesperidoside on the rat soleus muscle. J Nat Prod. 2008 Apr;71(4):532-5. Epub 2008 Feb 28. PubMed PMID: 18303854.
7: Adachi Y, Yoshikawa Y, Sakurai H. Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities. Biofactors. 2007;29(4):213-23. PubMed PMID: 18057552.
8: Yasumatsu N, Yoshikawa Y, Adachi Y, Sakurai H. Antidiabetic copper(II)-picolinate: impact of the first transition metal in the metallopicolinate complexes. Bioorg Med Chem. 2007 Jul 15;15(14):4917-22. Epub 2007 May 5. PubMed PMID: 17531495.
9: Basuki W, Hiromura M, Sakurai H. Insulinomimetic Zn complex (Zn(opt)2) enhances insulin signaling pathway in 3T3-L1 adipocytes. J Inorg Biochem. 2007 Apr;101(4):692-9. Epub 2007 Jan 17. PubMed PMID: 17316811.
10: Yibchok-anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH.
Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull. 2006 Jun;29(6):1126-31. PubMed PMID: 16755004.
11: Mueller AS, Pallauf J. Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. J Nutr Biochem. 2006 Aug;17(8):548-60. Epub 2005 Nov 9. PubMed PMID: 16443359.
12: Haase H, Maret W. Fluctuations of cellular, available zinc modulate insulin signaling via inhibition of protein tyrosine phosphatases. J Trace Elem Med Biol. 2005;19(1):37-42. PubMed PMID: 16240670.
13: Haase H, Maret W. Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals. 2005 Aug;18(4):333-8. Review. PubMed PMID: 16158225.
14: Sakurai H, Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals. 2005 Aug;18(4):319-23. Review. PubMed PMID: 16158223.
15: Pinent M, Bladé MC, Salvadó MJ, Arola L, Ardévol A. Metabolic fate of glucose on 3T3-L1 adipocytes treated with grape seed-derived procyanidin extract (GSPE). Comparison with the effects of insulin. J Agric Food Chem. 2005 Jul 27;53(15):5932-5. PubMed PMID: 16028976.
16: Yoshikawa Y, Kondo M, Sakurai H, Kojima Y. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n=3 and 4) coordination modes. J Inorg Biochem. 2005 Jul;99(7):1497-503. PubMed PMID: 15921760.
17: Fugono J, Fujimoto K, Yasui H, Kawabe K, Yoshikawa Y, Kojima Y, Sakurai H. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc(II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration. Drug Metab Pharmacokinet. 2002;17(4):340-7. PubMed PMID: 15618684.
18: Jorge AP, Horst H, de Sousa E, Pizzolatti MG, Silva FR. Insulinomimetic effects of kaempferitrin on glycaemia and on 14C-glucose uptake in rat soleus muscle. Chem Biol Interact. 2004 Oct 15;149(2-3):89-96. PubMed PMID: 15501431.
19: Pinent M, Blay M, Bladé MC, Salvadó MJ, Arola L, Ardévol A. Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology. 2004 Nov;145(11):4985-90. Epub 2004 Jul 22. PubMed PMID: 15271880.
20: Yoshikawa Y, Ueda E, Kojima Y, Sakurai H. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sci. 2004 Jun 25;75(6):741-51. PubMed PMID: 15172182.
21: Yoshikawa Y, Ueda E, Kawabe K, Miyake H, Takino T, Sakurai H, Kojima Y. Development of new insulinomimetic zinc(II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization, in vitro, and in vivo studies. J Biol Inorg Chem. 2002 Jan;7(1-2):68-73. Epub 2001 Jul 11. PubMed PMID: 11862542.
22: Yoshikawa Y, Ueda E, Suzuki Y, Yanagihara N, Sakurai H, Kojima Y. New insulinomimetic zinc(II) complexes of alpha-amino acids and their derivatives with Zn(N2O2) coordination mode. Chem Pharm Bull (Tokyo). 2001 May;49(5):652-4. PubMed PMID: 11383627.
23: Yoshikawa Y, Ueda E, Miyake H, Sakurai H, Kojima Y. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus. Biochem Biophys Res Commun. 2001 Mar;281(5):1190-3. PubMed PMID: 11243860.
40: Pelletier A, Tardif A, Gingras MH, Chiasson JL, Coderre L. Chronic exposure
to ketone bodies impairs glucose uptake in adult cardiomyocytes in response to
insulin but not vanadate: the role of PI3-K. Mol Cell Biochem. 2007
Feb;296(1-2):97-108. Epub 2006 Sep 8. PubMed PMID: 16960657.
42: Gad MZ, El-Sawalhi MM, Ismail MF, El-Tanbouly ND. Biochemical study of the anti-diabetic action of the Egyptian plants fenugreek and balanites. Mol Cell
48: Coderre L, Srivastava AK. Vanadium and the cardiovascular functions. Can J
Physiol Pharmacol. 2004 Oct;82(10):833-9. Review. PubMed PMID: 15573143.
59: Haase H, Maret W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp Cell
Res. 2003 Dec 10;291(2):289-98. PubMed PMID: 14644152.
60: Mueller AS, Pallauf J, Rafael J. The chemical form of selenium affects insulinomimetic properties of the trace element: investigations in type II diabetic dbdb mice. J Nutr Biochem. 2003 Nov;14(11):637-47. PubMed PMID: 14629895.
63: Kojima Y, Yoshikawa Y, Ueda E, Ueda R, Yamamoto S, Kumekawa K, Yanagihara N, Sakurai H. Insulinomimetic zinc(II) complexes with natural products: in vitro evaluation and blood glucose lowering effect in KK-Ay mice with type 2 diabetes mellitus. Chem Pharm Bull (Tokyo). 2003 Aug;51(8):1006-8. PubMed PMID: 12913247.
68: Yoshikawa Y, Ueda E, Sakurai H, Kojima Y. Anti-diabetes effect of Zn(II)/carnitine complex by oral administration. Chem Pharm Bull (Tokyo). 2003 Feb;51(2):230-1. PubMed PMID: 12576666.
96: Amessou M, Bortoli S, Liemans V, Collinet M, Desbuquois B, Brichard S, Girard
J. Treatment of streptozotocin-induced diabetic rats with vanadate and phlorizin prevents the over-expression of the liver insulin receptor gene. Eur J Endocrinol. 1999 Jan;140(1):79-86. PubMed PMID: 10037256.
109: Ong KC, Khoo HE. Insulinomimetic effects of myricetin on lipogenesis and glucose transport in rat adipocytes but not glucose transport translocation. Biochem Pharmacol. 1996 Feb 23;51(4):423-9. PubMed PMID: 8619886.
113: Goto Y, Kida K. Insulin-like action of chromate on glucose transport in isolated rat adipocytes. Jpn J Pharmacol. 1995 Apr;67(4):365-8. PubMed PMID: 7650869.
116: Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G. Effects of
chronic vanadate administration in the STZ-induced diabetic rat. The
antihyperglycemic action of vanadate is attributable entirely to its suppression
of feeding. Diabetes. 1994 Jan;43(1):9-15. PubMed PMID: 8262323.
117: Watkins JB 3rd, Bauman ME, Beaty TM. Effect of sodium orthovanadate on the hepatobiliary clearance of rose bengal in streptozotocin-induced diabetic rats. Biochem Pharmacol. 1993 Dec 14;46(12):2269-76. PubMed PMID: 8274160.
derived peptide. J Biol
Chem. 1993 Jan 25;268(3):1770-4. PubMed PMID: 8420953.
125: Hadari YR, Tzahar E, Nadiv O, Rothenberg P, Roberts CT Jr, LeRoith D, Yarden
Y, Zick Y. Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers. J Biol Chem. 1992 Sep 5;267(25):17483-6. Erratum in: J Biol Chem 1993 Apr 25;268(12):9156. PubMed PMID: 1381348.
126: Shisheva A, Shechter Y. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry. 1992 Sep 1;31(34):8059-63. PubMed PMID: 1324726.
130: Rossetti L, Giaccari A, Klein-Robbenhaar E, Vogel LR. Insulinomimetic properties of trace elements and characterization of their in vivo mode of action. Diabetes. 1990 Oct;39(10):1243-50. PubMed PMID: 2210077.
144: Pershadsingh HA, Gale RD, McDonald JM. Chelation of intracellular calcium prevents stimulation of glucose transport by insulin and insulinomimetic agents in the adipocyte. Evidence for a common mechanism. Endocrinology. 1987 Nov;121(5):1727-32. PubMed PMID: 3311718.
146: Ng TB, Wong CM, Li WW, Yeung HW. Acid-ethanol extractable compounds from fruits and seeds of the bitter gourd Momordica charantia: effects on lipid metabolism in isolated rat adipocytes. Am J Chin Med. 1987;15(1-2):31-42. PubMed PMID: 3318384.
147: Helm BA, Gunn JM. The effect of insulinomimetic agents on protein degradation in H35 hepatoma cells. Mol Cell Biochem. 1986 Aug;71(2):159-66. PubMed PMID: 3534545.
148: Ng TB, Wong CM, Li WW, Yeung HW. Isolation and characterization of a galactose binding lectin with insulinomimetic activities. From the seeds of the bitter gourd Momordica charantia (Family Cucurbitaceae). Int J Pept Protein Res. 1986 Aug;28(2):163-72. PubMed PMID: 3533814.
150: Yeung HW, Ng TB, Wong DM, Wong CM, Li WW. Chemical and biological characterization of the galactose binding lectins from Trichosanthes kirilowii root tubers. Int J Pept Protein Res. 1986 Feb;27(2):208-20. PubMed PMID: 3084399.
151: Subasinghe S, Greenbaum AL, McLean P. The insulin-mimetic action of Mn2+: involvement of cyclic nucleotides and insulin in the regulation of hepatic hexokinase and glucokinase. Biochem Med. 1985 Aug;34(1):83-92. PubMed PMID: 2996512.
152: Grunfeld C, Jones DS, Shigenaga JK. Autoantibodies against the insulin receptor. Dissociation of the acute effects of the antibodies from the desensitization seen with prolonged exposure. Diabetes. 1985 Mar;34(3):205-11. PubMed PMID: 3882486.
155: Grunfeld C. Antibody against the insulin receptor causes disappearance of insulin receptors in 3T3-L1 cells: a possible explanation of antibody-induced insulin resistance. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2508-11. PubMed PMID: 6371815; PubMed Central PMCID: PMC345091.
156: Simpson IA, Hedo JA. Insulin receptor phosphorylation may not be a prerequisite for acute insulin action. Science. 1984 Mar 23;223(4642):1301-4. PubMed PMID: 6367041.
157: Shechter Y. Bound lectins that mimic insulin produce persistent insulin-like activities. Endocrinology. 1983 Dec;113(6):1921-6. PubMed PMID: 6357762.
161: Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med. 1982 Dec 2;307(23):1422-6. PubMed PMID: 7133096.
166: Pillion DJ, Carter-Su CA, Pilch PF, Czech MP. Isolation of adipocyte plasma membrane antigens by immunoaffinity chromatography. Insulinomimetic antibodies do not bind directly to the insulin receptor or the glucose transport system. J Biol Chem. 1980 Oct 10;255(19):9168-76. PubMed PMID: 6773960.
167: Beachy JC, Czech MP. Production of insulinomimetic antibodies against rat adipocyte membranes by hybridoma cells. J Supramol Struct. 1980;13(4):447-56. PubMed PMID: 7230801.
170: Balasse E, Rasio E, Conard V. [Insulinomimetic action of vasopressin in the dog]. Arch Int Pharmacodyn Ther. 1966 Jun;161(2):392-7. French. PubMed PMID: 5926881.
171: Cai EP, Lin JK. Epigallocatechin Gallate (EGCG) and Rutin Suppress the Glucotoxicity through Activating IRS2 and AMPK Signaling in Rat Pancreatic beta Cells. J Agric Food Chem. 2009 Oct 5. [Epub ahead of print] PubMed PMID: 19803520.
172: Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. Ann N Y Acad Sci. 2009 Aug;1171:538-44. PubMed PMID: 19723101.
173: Way TD, Lin HY, Kuo DH, Tsai SJ, Shieh JC, Wu JC, Lee MR, Lin JK. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 2009 Jun 24;57(12):5257-64. PubMed PMID: 19459711.
174: Murase T, Misawa K, Haramizu S, Hase T. Catechin-induced activation of the LKB1/AMP-activated protein kinase pathway. Biochem Pharmacol. 2009 Jul 1;78(1):78-84. Epub 2009 Mar 31. PubMed PMID: 19447226.
175: Lin CL, Lin JK. Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells. Mol Nutr Food Res. 2008 Aug;52(8):930-9. PubMed PMID: 18496818.
176: Collins QF, Liu HY, Pi J, Liu Z, Quon MJ, Cao W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J Biol Chem. 2007 Oct 12;282(41):30143-9. Epub 2007 Aug 27. PubMed PMID: 17724029; PubMed Central PMCID: PMC2408735.
177: Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res. 2007 Nov;48(11):2334-43. Epub 2007 Aug 24. PubMed PMID: 17720960.
1: Cazarolli LH, Folador P, Moresco HH, Brighente IM, Pizzolatti MG, Silva FR.
Stimulatory effect of apigenin-6-C-beta-L-fucopyranoside on insulin secretion and glycogen synthesis. Eur J Med Chem. 2009 Nov;44(11):4668-73. Epub 2009 Jul 9. PubMed PMID: 19625113.
2: Montagut G, Onnockx S, Vaqué M, Bladé C, Blay M, Fernández-Larrea J, Pujadas
G, Salvadó MJ, Arola L, Pirson I, Ardévol A, Pinent M. Oligomers of grape-seed procyanidin extract activate the insulin receptor and key targets of the insulin signaling pathway differently from insulin. J Nutr Biochem. 2009 May 13. [Epub ahead of print] PubMed PMID: 19443198.
3: Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14070-5. Epub 2008 Sep 8. PubMed PMID: 18779578; PubMed Central PMCID:
PMC2544580.
4: Aydemir-Koksoy A, Turan B. Selenium inhibits proliferation signaling and restores sodium/potassium pump function of diabetic rat aorta. Biol Trace Elem Res. 2008 Winter;126(1-3):237-45. Epub 2008 Aug 14. PubMed PMID: 18704274.
5: Nishide M, Yoshikawa Y, Yoshikawa EU, Matsumoto K, Sakurai H, Kajiwara NM.
Insulinomimetic Zn(II) complexes as evaluated by both glucose-uptake activity and inhibition of free fatty acids release in isolated rat adipocytes. Chem Pharm Bull (Tokyo). 2008 Aug;56(8):1181-3. PubMed PMID: 18670123.
6: Zanatta L, Rosso A, Folador P, Figueiredo MS, Pizzolatti MG, Leite LD, Silva
FR. Insulinomimetic effect of kaempferol 3-neohesperidoside on the rat soleus muscle. J Nat Prod. 2008 Apr;71(4):532-5. Epub 2008 Feb 28. PubMed PMID: 18303854.
7: Adachi Y, Yoshikawa Y, Sakurai H. Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities. Biofactors. 2007;29(4):213-23. PubMed PMID: 18057552.
8: Yasumatsu N, Yoshikawa Y, Adachi Y, Sakurai H. Antidiabetic copper(II)-picolinate: impact of the first transition metal in the metallopicolinate complexes. Bioorg Med Chem. 2007 Jul 15;15(14):4917-22. Epub 2007 May 5. PubMed PMID: 17531495.
9: Basuki W, Hiromura M, Sakurai H. Insulinomimetic Zn complex (Zn(opt)2) enhances insulin signaling pathway in 3T3-L1 adipocytes. J Inorg Biochem. 2007 Apr;101(4):692-9. Epub 2007 Jan 17. PubMed PMID: 17316811.
10: Yibchok-anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH.
Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull. 2006 Jun;29(6):1126-31. PubMed PMID: 16755004.
11: Mueller AS, Pallauf J. Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. J Nutr Biochem. 2006 Aug;17(8):548-60. Epub 2005 Nov 9. PubMed PMID: 16443359.
12: Haase H, Maret W. Fluctuations of cellular, available zinc modulate insulin signaling via inhibition of protein tyrosine phosphatases. J Trace Elem Med Biol. 2005;19(1):37-42. PubMed PMID: 16240670.
13: Haase H, Maret W. Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals. 2005 Aug;18(4):333-8. Review. PubMed PMID: 16158225.
14: Sakurai H, Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals. 2005 Aug;18(4):319-23. Review. PubMed PMID: 16158223.
15: Pinent M, Bladé MC, Salvadó MJ, Arola L, Ardévol A. Metabolic fate of glucose on 3T3-L1 adipocytes treated with grape seed-derived procyanidin extract (GSPE). Comparison with the effects of insulin. J Agric Food Chem. 2005 Jul 27;53(15):5932-5. PubMed PMID: 16028976.
16: Yoshikawa Y, Kondo M, Sakurai H, Kojima Y. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n=3 and 4) coordination modes. J Inorg Biochem. 2005 Jul;99(7):1497-503. PubMed PMID: 15921760.
17: Fugono J, Fujimoto K, Yasui H, Kawabe K, Yoshikawa Y, Kojima Y, Sakurai H. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc(II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration. Drug Metab Pharmacokinet. 2002;17(4):340-7. PubMed PMID: 15618684.
18: Jorge AP, Horst H, de Sousa E, Pizzolatti MG, Silva FR. Insulinomimetic effects of kaempferitrin on glycaemia and on 14C-glucose uptake in rat soleus muscle. Chem Biol Interact. 2004 Oct 15;149(2-3):89-96. PubMed PMID: 15501431.
19: Pinent M, Blay M, Bladé MC, Salvadó MJ, Arola L, Ardévol A. Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology. 2004 Nov;145(11):4985-90. Epub 2004 Jul 22. PubMed PMID: 15271880.
20: Yoshikawa Y, Ueda E, Kojima Y, Sakurai H. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sci. 2004 Jun 25;75(6):741-51. PubMed PMID: 15172182.
21: Yoshikawa Y, Ueda E, Kawabe K, Miyake H, Takino T, Sakurai H, Kojima Y. Development of new insulinomimetic zinc(II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization, in vitro, and in vivo studies. J Biol Inorg Chem. 2002 Jan;7(1-2):68-73. Epub 2001 Jul 11. PubMed PMID: 11862542.
22: Yoshikawa Y, Ueda E, Suzuki Y, Yanagihara N, Sakurai H, Kojima Y. New insulinomimetic zinc(II) complexes of alpha-amino acids and their derivatives with Zn(N2O2) coordination mode. Chem Pharm Bull (Tokyo). 2001 May;49(5):652-4. PubMed PMID: 11383627.
23: Yoshikawa Y, Ueda E, Miyake H, Sakurai H, Kojima Y. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus. Biochem Biophys Res Commun. 2001 Mar;281(5):1190-3. PubMed PMID: 11243860.
40: Pelletier A, Tardif A, Gingras MH, Chiasson JL, Coderre L. Chronic exposure
to ketone bodies impairs glucose uptake in adult cardiomyocytes in response to
insulin but not vanadate: the role of PI3-K. Mol Cell Biochem. 2007
Feb;296(1-2):97-108. Epub 2006 Sep 8. PubMed PMID: 16960657.
42: Gad MZ, El-Sawalhi MM, Ismail MF, El-Tanbouly ND. Biochemical study of the anti-diabetic action of the Egyptian plants fenugreek and balanites. Mol Cell
48: Coderre L, Srivastava AK. Vanadium and the cardiovascular functions. Can J
Physiol Pharmacol. 2004 Oct;82(10):833-9. Review. PubMed PMID: 15573143.
59: Haase H, Maret W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp Cell
Res. 2003 Dec 10;291(2):289-98. PubMed PMID: 14644152.
60: Mueller AS, Pallauf J, Rafael J. The chemical form of selenium affects insulinomimetic properties of the trace element: investigations in type II diabetic dbdb mice. J Nutr Biochem. 2003 Nov;14(11):637-47. PubMed PMID: 14629895.
63: Kojima Y, Yoshikawa Y, Ueda E, Ueda R, Yamamoto S, Kumekawa K, Yanagihara N, Sakurai H. Insulinomimetic zinc(II) complexes with natural products: in vitro evaluation and blood glucose lowering effect in KK-Ay mice with type 2 diabetes mellitus. Chem Pharm Bull (Tokyo). 2003 Aug;51(8):1006-8. PubMed PMID: 12913247.
68: Yoshikawa Y, Ueda E, Sakurai H, Kojima Y. Anti-diabetes effect of Zn(II)/carnitine complex by oral administration. Chem Pharm Bull (Tokyo). 2003 Feb;51(2):230-1. PubMed PMID: 12576666.
96: Amessou M, Bortoli S, Liemans V, Collinet M, Desbuquois B, Brichard S, Girard
J. Treatment of streptozotocin-induced diabetic rats with vanadate and phlorizin prevents the over-expression of the liver insulin receptor gene. Eur J Endocrinol. 1999 Jan;140(1):79-86. PubMed PMID: 10037256.
109: Ong KC, Khoo HE. Insulinomimetic effects of myricetin on lipogenesis and glucose transport in rat adipocytes but not glucose transport translocation. Biochem Pharmacol. 1996 Feb 23;51(4):423-9. PubMed PMID: 8619886.
113: Goto Y, Kida K. Insulin-like action of chromate on glucose transport in isolated rat adipocytes. Jpn J Pharmacol. 1995 Apr;67(4):365-8. PubMed PMID: 7650869.
116: Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G. Effects of
chronic vanadate administration in the STZ-induced diabetic rat. The
antihyperglycemic action of vanadate is attributable entirely to its suppression
of feeding. Diabetes. 1994 Jan;43(1):9-15. PubMed PMID: 8262323.
117: Watkins JB 3rd, Bauman ME, Beaty TM. Effect of sodium orthovanadate on the hepatobiliary clearance of rose bengal in streptozotocin-induced diabetic rats. Biochem Pharmacol. 1993 Dec 14;46(12):2269-76. PubMed PMID: 8274160.
derived peptide. J Biol
Chem. 1993 Jan 25;268(3):1770-4. PubMed PMID: 8420953.
125: Hadari YR, Tzahar E, Nadiv O, Rothenberg P, Roberts CT Jr, LeRoith D, Yarden
Y, Zick Y. Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers. J Biol Chem. 1992 Sep 5;267(25):17483-6. Erratum in: J Biol Chem 1993 Apr 25;268(12):9156. PubMed PMID: 1381348.
126: Shisheva A, Shechter Y. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry. 1992 Sep 1;31(34):8059-63. PubMed PMID: 1324726.
130: Rossetti L, Giaccari A, Klein-Robbenhaar E, Vogel LR. Insulinomimetic properties of trace elements and characterization of their in vivo mode of action. Diabetes. 1990 Oct;39(10):1243-50. PubMed PMID: 2210077.
144: Pershadsingh HA, Gale RD, McDonald JM. Chelation of intracellular calcium prevents stimulation of glucose transport by insulin and insulinomimetic agents in the adipocyte. Evidence for a common mechanism. Endocrinology. 1987 Nov;121(5):1727-32. PubMed PMID: 3311718.
146: Ng TB, Wong CM, Li WW, Yeung HW. Acid-ethanol extractable compounds from fruits and seeds of the bitter gourd Momordica charantia: effects on lipid metabolism in isolated rat adipocytes. Am J Chin Med. 1987;15(1-2):31-42. PubMed PMID: 3318384.
147: Helm BA, Gunn JM. The effect of insulinomimetic agents on protein degradation in H35 hepatoma cells. Mol Cell Biochem. 1986 Aug;71(2):159-66. PubMed PMID: 3534545.
148: Ng TB, Wong CM, Li WW, Yeung HW. Isolation and characterization of a galactose binding lectin with insulinomimetic activities. From the seeds of the bitter gourd Momordica charantia (Family Cucurbitaceae). Int J Pept Protein Res. 1986 Aug;28(2):163-72. PubMed PMID: 3533814.
150: Yeung HW, Ng TB, Wong DM, Wong CM, Li WW. Chemical and biological characterization of the galactose binding lectins from Trichosanthes kirilowii root tubers. Int J Pept Protein Res. 1986 Feb;27(2):208-20. PubMed PMID: 3084399.
151: Subasinghe S, Greenbaum AL, McLean P. The insulin-mimetic action of Mn2+: involvement of cyclic nucleotides and insulin in the regulation of hepatic hexokinase and glucokinase. Biochem Med. 1985 Aug;34(1):83-92. PubMed PMID: 2996512.
152: Grunfeld C, Jones DS, Shigenaga JK. Autoantibodies against the insulin receptor. Dissociation of the acute effects of the antibodies from the desensitization seen with prolonged exposure. Diabetes. 1985 Mar;34(3):205-11. PubMed PMID: 3882486.
155: Grunfeld C. Antibody against the insulin receptor causes disappearance of insulin receptors in 3T3-L1 cells: a possible explanation of antibody-induced insulin resistance. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2508-11. PubMed PMID: 6371815; PubMed Central PMCID: PMC345091.
156: Simpson IA, Hedo JA. Insulin receptor phosphorylation may not be a prerequisite for acute insulin action. Science. 1984 Mar 23;223(4642):1301-4. PubMed PMID: 6367041.
157: Shechter Y. Bound lectins that mimic insulin produce persistent insulin-like activities. Endocrinology. 1983 Dec;113(6):1921-6. PubMed PMID: 6357762.
161: Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med. 1982 Dec 2;307(23):1422-6. PubMed PMID: 7133096.
166: Pillion DJ, Carter-Su CA, Pilch PF, Czech MP. Isolation of adipocyte plasma membrane antigens by immunoaffinity chromatography. Insulinomimetic antibodies do not bind directly to the insulin receptor or the glucose transport system. J Biol Chem. 1980 Oct 10;255(19):9168-76. PubMed PMID: 6773960.
167: Beachy JC, Czech MP. Production of insulinomimetic antibodies against rat adipocyte membranes by hybridoma cells. J Supramol Struct. 1980;13(4):447-56. PubMed PMID: 7230801.
170: Balasse E, Rasio E, Conard V. [Insulinomimetic action of vasopressin in the dog]. Arch Int Pharmacodyn Ther. 1966 Jun;161(2):392-7. French. PubMed PMID: 5926881.
171: Cai EP, Lin JK. Epigallocatechin Gallate (EGCG) and Rutin Suppress the Glucotoxicity through Activating IRS2 and AMPK Signaling in Rat Pancreatic beta Cells. J Agric Food Chem. 2009 Oct 5. [Epub ahead of print] PubMed PMID: 19803520.
172: Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. Ann N Y Acad Sci. 2009 Aug;1171:538-44. PubMed PMID: 19723101.
173: Way TD, Lin HY, Kuo DH, Tsai SJ, Shieh JC, Wu JC, Lee MR, Lin JK. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 2009 Jun 24;57(12):5257-64. PubMed PMID: 19459711.
174: Murase T, Misawa K, Haramizu S, Hase T. Catechin-induced activation of the LKB1/AMP-activated protein kinase pathway. Biochem Pharmacol. 2009 Jul 1;78(1):78-84. Epub 2009 Mar 31. PubMed PMID: 19447226.
175: Lin CL, Lin JK. Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells. Mol Nutr Food Res. 2008 Aug;52(8):930-9. PubMed PMID: 18496818.
176: Collins QF, Liu HY, Pi J, Liu Z, Quon MJ, Cao W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J Biol Chem. 2007 Oct 12;282(41):30143-9. Epub 2007 Aug 27. PubMed PMID: 17724029; PubMed Central PMCID: PMC2408735.
177: Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res. 2007 Nov;48(11):2334-43. Epub 2007 Aug 24. PubMed PMID: 17720960.
Sunday, October 18, 2009
Tuesday, October 13, 2009
Bill Frist is Pro-Swine Flu Vaccine, Bill Maher is Correct
There is no weird new virus, "Swine Flu." There IS ONLY FLU VIRUS. It is intrinsically no different than any other flu virus. How can a new vaccine do any different for any new flu when each flu at its core is the same. Nevermind synthetic molecules for flu which have extremely poor efficacy. Flu virus is HxNy, with nine variants of H (H1,H2,H3,H4,H5,H6,H7,H8,H9) at least 3 variants of N (N1,N2,N3) and any number of permutations of these hemagluttinins and neuraminidases. There can also be SNP mutations in its code, but it is still a flu virus. Pathogenicity may differ strain to strain, but from my own memory, regular old flu is pretty damn bad, never mind a new flu. The worst flu virus can only be as pathogenic as flu can be. Given modern American hygiene, clean environments, sanitation, nutrition, and living standards, there can be no pandemic unless some evil group intentionally starts one.
When a dog catches a cold, you have a cold, and you catch your dog's cold, the cold virii may mix. Still, it is not then the "Dog Cold Virus." If the dog virus had some manmade cytotoxic genetic elements intentionally inserted into it, and then it got into the human epidemiology, I would be worried. But otherwise, it is still cold virus. The fear was sparked by the poultry farms in which animals were crammed together in close quarter in poor hygiene environments, which inevitably generate an exponential vector situation for an aerosol disease.
The innate immunological approach is proving to be a good one in many aspects and endeavors of human health.
When a dog catches a cold, you have a cold, and you catch your dog's cold, the cold virii may mix. Still, it is not then the "Dog Cold Virus." If the dog virus had some manmade cytotoxic genetic elements intentionally inserted into it, and then it got into the human epidemiology, I would be worried. But otherwise, it is still cold virus. The fear was sparked by the poultry farms in which animals were crammed together in close quarter in poor hygiene environments, which inevitably generate an exponential vector situation for an aerosol disease.
The innate immunological approach is proving to be a good one in many aspects and endeavors of human health.
Sunday, October 4, 2009
Preventing Atherosclerosis in Rabbits Fed 1% Cholesterol Diets w/Yerba Mate Tea
1: Biofactors. 2006;26(1):59-70.
Aqueous extract of Ilex paraguariensis attenuates the progression of
atherosclerosis in cholesterol-fed rabbits.
Mosimann AL, Wilhelm-Filho D, da Silva EL.
Department of Clinical Analysis, Health Sciences Center, Federal University of
Santa Catarina, Florianópolis, SC, Brazil.
Ilex paraguariensis aqueous extract (mate) is an antioxidant-rich beverage widely consumed in South American countries. Here we questioned whether mate could reduce the progression of atherosclerosis in 1% cholesterol-fed rabbits. New Zealand White male rabbits (n = 32) were divided into four groups: control (C, n = 5),control-mate (CM, n = 5), hypercholesterolemic (HC, n = 11) and hypercholesterolemic-mate (HCM, = 11). The daily water and mate extract consumption was approximately 400 ml. After 2 months of treatment, mate intake did not change the lipid profile or hepatic cholesterol content of control or hypercholesterolemic rabbits (p < 0.05). However, the atherosclerotic lesion area was considerably smaller in the hypercholesterolemic-mate group (HCM, 35.4% vs. HC, 60.1%; p < 0.05). In addition, the aortic cholesterol content was around half that of the HC group (HCM, 36.8 vs. HC, 73.9 microg/mg of protein, p < 0.05). In spite of this, the thiobarbituric acid-reactive substances (TBARS) in the atherosclerotic aorta, liver and serum, and the activity of the antioxidant enzymes in liver and aorta did not differ among groups (p > 0.05). The results showed that Ilex paraguariensis extract can inhibit the progression of atherosclerosis in cholesterol-fed rabbits, although it did not decrease the serum cholesterol or aortic TBARS and antioxidant enzymes.
PMID: 16614483 [PubMed - indexed for MEDLINE]
Related Links
The effect of ethanol extract of Hypericum lysimachioides on lipid profile in
hypercholesterolemic rabbits and its in vitro antioxidant activity.
[Atherosclerosis. 2007] PMID:16901489
Polygonatum rhizoma affects antioxidant defense systems without changing mRNA
expression in diet-induced hypercholesterolemic rabbits. [J Med Food. 2004]
PMID:15383232
Proanthocyanidin-rich extract from grape seeds attenuates the development of
aortic atherosclerosis in cholesterol-fed rabbits. [Atherosclerosis. 1999]
PMID:9920515
Changes in antioxidant defense status in hypercholesterolemic rats treated with
Ajuga iva. [Phytomedicine. 2008] PMID:18068964
Effects of defibrotide on aorta and brain malondialdehyde and antioxidants in
cholesterol-induced atherosclerotic rabbits. [Int J Clin Lab Res. 2000]
PMID:11043504
Aqueous extract of Ilex paraguariensis attenuates the progression of
atherosclerosis in cholesterol-fed rabbits.
Mosimann AL, Wilhelm-Filho D, da Silva EL.
Department of Clinical Analysis, Health Sciences Center, Federal University of
Santa Catarina, Florianópolis, SC, Brazil.
Ilex paraguariensis aqueous extract (mate) is an antioxidant-rich beverage widely consumed in South American countries. Here we questioned whether mate could reduce the progression of atherosclerosis in 1% cholesterol-fed rabbits. New Zealand White male rabbits (n = 32) were divided into four groups: control (C, n = 5),control-mate (CM, n = 5), hypercholesterolemic (HC, n = 11) and hypercholesterolemic-mate (HCM, = 11). The daily water and mate extract consumption was approximately 400 ml. After 2 months of treatment, mate intake did not change the lipid profile or hepatic cholesterol content of control or hypercholesterolemic rabbits (p < 0.05). However, the atherosclerotic lesion area was considerably smaller in the hypercholesterolemic-mate group (HCM, 35.4% vs. HC, 60.1%; p < 0.05). In addition, the aortic cholesterol content was around half that of the HC group (HCM, 36.8 vs. HC, 73.9 microg/mg of protein, p < 0.05). In spite of this, the thiobarbituric acid-reactive substances (TBARS) in the atherosclerotic aorta, liver and serum, and the activity of the antioxidant enzymes in liver and aorta did not differ among groups (p > 0.05). The results showed that Ilex paraguariensis extract can inhibit the progression of atherosclerosis in cholesterol-fed rabbits, although it did not decrease the serum cholesterol or aortic TBARS and antioxidant enzymes.
PMID: 16614483 [PubMed - indexed for MEDLINE]
Related Links
The effect of ethanol extract of Hypericum lysimachioides on lipid profile in
hypercholesterolemic rabbits and its in vitro antioxidant activity.
[Atherosclerosis. 2007] PMID:16901489
Polygonatum rhizoma affects antioxidant defense systems without changing mRNA
expression in diet-induced hypercholesterolemic rabbits. [J Med Food. 2004]
PMID:15383232
Proanthocyanidin-rich extract from grape seeds attenuates the development of
aortic atherosclerosis in cholesterol-fed rabbits. [Atherosclerosis. 1999]
PMID:9920515
Changes in antioxidant defense status in hypercholesterolemic rats treated with
Ajuga iva. [Phytomedicine. 2008] PMID:18068964
Effects of defibrotide on aorta and brain malondialdehyde and antioxidants in
cholesterol-induced atherosclerotic rabbits. [Int J Clin Lab Res. 2000]
PMID:11043504
From Linus Pauling to Dr. Rath to YOU:
Pay attention to it, or ignore it, it is your choice. Personally, I highly recommend you pay attention to it if you would avoid atherosclerosis.
Monday, September 21, 2009
Maslinic Acid (Olive Pomace Oil Molecule)
Very interesting in that it is a pentacyclic triterpenoid molecule that shares its scaffold versatility features with several other scaffold series, much like catechin, epicatechin, epigallocatechin, and epigallocatechin gallate which are variations on a theme.
A must read paper on Maslinic Acid.
Importantly, it must be understood that this is NOT olive oil or olive pomace oil, but a compound in olive pomace (skin wax) oil to be very specific. As with all medicine, delivery vehicle, oral bioavailability, Cmax, and pharmacokinetics must be considered before declaring it a feasible therapeutic. It seems good here, and more studies are warranted.
"1: Biol Pharm Bull. 2007 Nov;30(11):2075-8.
Maslinic acid reduces blood glucose in KK-Ay mice.
Liu J, Sun H, Duan W, Mu D, Zhang L.
National Drug Screening Center, China Pharmaceutical University, 1 Shennonglu,
Nanjing, China.
In the present study, we have examined the hypoglycemic effect of maslinic acid (MA) in KK-A(y) mice, an animal model of genetic type-2 diabetes. MA (10 mg/kg body wt) reduced the blood glucose levels in KK-A(y) mice at 4 h after a single oral dose. KK-A(y) mice receiving MA at daily dosages of 10 mg/kg and 30 mg/kg for 2 weeks showed a significant reduction in the blood glucose levels. Furthermore, the results also showed that MA might modulate glucose metabolism partially through reducing insulin resistance in KK-A(y) mice. Taken together, MA may hold great promise as a natural therapeutic agent for treatment of type 2 diabetes.
PMID: 17978478 [PubMed - indexed for MEDLINE]
"
A must read paper on Maslinic Acid.
Importantly, it must be understood that this is NOT olive oil or olive pomace oil, but a compound in olive pomace (skin wax) oil to be very specific. As with all medicine, delivery vehicle, oral bioavailability, Cmax, and pharmacokinetics must be considered before declaring it a feasible therapeutic. It seems good here, and more studies are warranted.
"1: Biol Pharm Bull. 2007 Nov;30(11):2075-8.
Maslinic acid reduces blood glucose in KK-Ay mice.
Liu J, Sun H, Duan W, Mu D, Zhang L.
National Drug Screening Center, China Pharmaceutical University, 1 Shennonglu,
Nanjing, China.
In the present study, we have examined the hypoglycemic effect of maslinic acid (MA) in KK-A(y) mice, an animal model of genetic type-2 diabetes. MA (10 mg/kg body wt) reduced the blood glucose levels in KK-A(y) mice at 4 h after a single oral dose. KK-A(y) mice receiving MA at daily dosages of 10 mg/kg and 30 mg/kg for 2 weeks showed a significant reduction in the blood glucose levels. Furthermore, the results also showed that MA might modulate glucose metabolism partially through reducing insulin resistance in KK-A(y) mice. Taken together, MA may hold great promise as a natural therapeutic agent for treatment of type 2 diabetes.
PMID: 17978478 [PubMed - indexed for MEDLINE]
"
Sunday, September 6, 2009
Thursday, September 3, 2009
Bone Anabolism from Dried Plum
Osteoporos Int. 2007 Jul;18(7):931-42. Epub 2007 Feb 15.
Comparison of dried plum supplementation and intermittent PTH in restoring bone
in osteopenic orchidectomized rats.
Bu SY, Lucas EA, Franklin M, Marlow D, Brackett DJ, Boldrin EA, Devareddy L,
Arjmandi BH, Smith BJ.
Department of Nutritional Sciences, College of Human Environmental Science,
Oklahoma State University, Stillwater, OK 74078, USA.
SUMMARY: Bone loss was confirmed after 90 days in 50 6-month-old male Sprague Dawley rats that were sham-operated or orchidectomized (ORX). In this study, we have shown that dried plum (DP) has potent effects on bone in terms of bone mass, microarchitecture, and strength in osteopenic male rats. Although these changes may be mediated through the suppression of bone resorption, the fact that the restoration in some of the bone structural and biomechanical parameter shares some similarities with parathyroid hormone (PTH) should not be overlooked. Further investigation is needed on a mechanistic level to clarify the influence of DP on bone metabolism. INTRODUCTION: This study was designed to investigate the extent to which DP reverses bone loss in osteopenic ORX rats and to compare its effects to PTH. MATERIALS AND METHODS: Fifty, 6-month-old male Sprague Dawley rats were sham-operated or ORX, and bone loss was confirmed after 90 days. The ORX groups were assigned to control (AIN-93M) diet, 25% DP diet, or PTH (80 microg/kg) for 90 days. RESULTS: DP induced an 11% increase in vertebral and femoral BMD compared to ORX-controls. BMD in the PTH-treated group was increased by 20.7% (vertebra) and 17.9% (femur). Vertebral trabecular bone volume (BV/TV) and number were increased by DP and trabecular separation was decreased compared to controls, which were similar to PTH. Alterations in trabecular bone of the femur were similar to those in the vertebra, but DP did not restore BV/TV to the same extent. Cortical thickness was improved by DP and further enhanced by PTH. DP tended to decrease urinary deoxypyridinoline and calcium, but did not alter alkaline phosphatase or osteocalcin. CONCLUSION: We conclude that though the degree of improvement was not equivalent to PTH with regard to all parameters, DP reverses bone loss due to ORX and the mechanisms should be further investigated.
PMID: 17554580 [PubMed - indexed for MEDLINE]
J Womens Health Gend Based Med. 2002 Jan-Feb;11(1):61-8.
Dried plums improve indices of bone formation in postmenopausal women.
Arjmandi BH, Khalil DA, Lucas EA, Georgis A, Stoecker BJ, Hardin C, Payton ME,
Wild RA.
Department of Nutritional Sciences, Oklahoma State University, Stillwater,
Oklahoma 74078-6141, USA.
Menopause drastically increases the risk of osteoporosis. Aside from drug therapy, lifestyle and nutritional factors play an important role in the maintenance of skeletal health. Our recent findings suggest that dried plums, a rich source of phenolic and flavonoid compounds, are highly effective in modulating bone mass in an ovarian hormone-deficient rat model of osteoporosis. The objective of this study was to examine whether the addition of dried plums to the diets of postmenopausal women positively influences markers of bone turnover. Fifty-eight postmenopausal women not on hormone replacement therapy (HRT) were randomly assigned to consume either 100 g dried plums or 75 g dried apples daily for 3 months. Both dried fruit regimens provided similar amount of calories, fat, carbohydrate, and fiber. Serum and urinary biochemical markers of bone status were assessed before and after treatment. In comparison with corresponding baseline values, only dried plums significantly increased serum levels of insulin-like growth factor-I (IGF-I) and bone-specific alkaline phosphatase(BSAP) activity. Higher levels of both serum IGF-I and BSAP are associated with greater rates of bone formation. Serum and urinary markers of bone resorption, however, were not affected by either dietary regimen. The results of this study suggest that dried plums may exert positive effects on bone in postmenopausal women. Longer duration studies are needed to confirm the beneficial effects of dried plum on bone mineral density (BMD) and the skeletal health of postmenopausal women.
PMID: 11860726 [PubMed - indexed for MEDLINE]
Comparison of dried plum supplementation and intermittent PTH in restoring bone
in osteopenic orchidectomized rats.
Bu SY, Lucas EA, Franklin M, Marlow D, Brackett DJ, Boldrin EA, Devareddy L,
Arjmandi BH, Smith BJ.
Department of Nutritional Sciences, College of Human Environmental Science,
Oklahoma State University, Stillwater, OK 74078, USA.
SUMMARY: Bone loss was confirmed after 90 days in 50 6-month-old male Sprague Dawley rats that were sham-operated or orchidectomized (ORX). In this study, we have shown that dried plum (DP) has potent effects on bone in terms of bone mass, microarchitecture, and strength in osteopenic male rats. Although these changes may be mediated through the suppression of bone resorption, the fact that the restoration in some of the bone structural and biomechanical parameter shares some similarities with parathyroid hormone (PTH) should not be overlooked. Further investigation is needed on a mechanistic level to clarify the influence of DP on bone metabolism. INTRODUCTION: This study was designed to investigate the extent to which DP reverses bone loss in osteopenic ORX rats and to compare its effects to PTH. MATERIALS AND METHODS: Fifty, 6-month-old male Sprague Dawley rats were sham-operated or ORX, and bone loss was confirmed after 90 days. The ORX groups were assigned to control (AIN-93M) diet, 25% DP diet, or PTH (80 microg/kg) for 90 days. RESULTS: DP induced an 11% increase in vertebral and femoral BMD compared to ORX-controls. BMD in the PTH-treated group was increased by 20.7% (vertebra) and 17.9% (femur). Vertebral trabecular bone volume (BV/TV) and number were increased by DP and trabecular separation was decreased compared to controls, which were similar to PTH. Alterations in trabecular bone of the femur were similar to those in the vertebra, but DP did not restore BV/TV to the same extent. Cortical thickness was improved by DP and further enhanced by PTH. DP tended to decrease urinary deoxypyridinoline and calcium, but did not alter alkaline phosphatase or osteocalcin. CONCLUSION: We conclude that though the degree of improvement was not equivalent to PTH with regard to all parameters, DP reverses bone loss due to ORX and the mechanisms should be further investigated.
PMID: 17554580 [PubMed - indexed for MEDLINE]
J Womens Health Gend Based Med. 2002 Jan-Feb;11(1):61-8.
Dried plums improve indices of bone formation in postmenopausal women.
Arjmandi BH, Khalil DA, Lucas EA, Georgis A, Stoecker BJ, Hardin C, Payton ME,
Wild RA.
Department of Nutritional Sciences, Oklahoma State University, Stillwater,
Oklahoma 74078-6141, USA.
Menopause drastically increases the risk of osteoporosis. Aside from drug therapy, lifestyle and nutritional factors play an important role in the maintenance of skeletal health. Our recent findings suggest that dried plums, a rich source of phenolic and flavonoid compounds, are highly effective in modulating bone mass in an ovarian hormone-deficient rat model of osteoporosis. The objective of this study was to examine whether the addition of dried plums to the diets of postmenopausal women positively influences markers of bone turnover. Fifty-eight postmenopausal women not on hormone replacement therapy (HRT) were randomly assigned to consume either 100 g dried plums or 75 g dried apples daily for 3 months. Both dried fruit regimens provided similar amount of calories, fat, carbohydrate, and fiber. Serum and urinary biochemical markers of bone status were assessed before and after treatment. In comparison with corresponding baseline values, only dried plums significantly increased serum levels of insulin-like growth factor-I (IGF-I) and bone-specific alkaline phosphatase(BSAP) activity. Higher levels of both serum IGF-I and BSAP are associated with greater rates of bone formation. Serum and urinary markers of bone resorption, however, were not affected by either dietary regimen. The results of this study suggest that dried plums may exert positive effects on bone in postmenopausal women. Longer duration studies are needed to confirm the beneficial effects of dried plum on bone mineral density (BMD) and the skeletal health of postmenopausal women.
PMID: 11860726 [PubMed - indexed for MEDLINE]
Monday, August 31, 2009
Statins Used As Immunosuppressants
There are a new batch of papers that demonstrate statins' anti-inflammatory effect. Yes it's true. If you shut off your immune system, you won't have any inflammation! Yet, scientists have known for at least a decade that statins have a dose-dependent immunosuppression effect.
1: J Heart Lung Transplant. 1998 Apr;17(4):335-40.
The inhibitory effects of pravastatin on natural killer cell activity in vivo and
on cytotoxic T lymphocyte activity in vitro.
Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Terasaki PI,
Kobashigawa JA.
Division of Nephrology, University of California, Davis, School of Medicine,
Sacramento, USA.
BACKGROUND: We have reported that heart transplant recipients treated with pravastatin demonstrate decreases in the incidence of clinically severe acute rejection episodes, the incidence and progression of transplant coronary vasculopathy, and natural killer cytotoxicity. These patients also exhibited a significant improvement in 1-year allograft survival. Because of these clinical findings suggesting an immunosuppressive effect of pravastatin unique to transplant recipients and the unclear role of natural killer cells in allograft rejection, we postulated that pravastatin may exert its immunomodulatory effect by acting with cyclosporine to alter T lymphocyte function. METHODS: Twenty patients randomized into an ongoing trial of pravastatin after heart transplantation were monitored serially for natural killer cell cytotoxicity. In a separate experiment, lymphocytes isolated from normal volunteers were treated with various combinations of pravastatin and cyclosporine and tested for cytotoxic T lymphocyte toxicity in a one-way mixed lymphocyte reaction. RESULTS: Pravastatin-treated heart transplant recipients exhibited a decrease in natural killer cell cytotoxicity (9.8% mean natural killer cell cytotoxicity vs 22.1% in the control group, p < 0.01). In the one-way mixed lymphocyte reaction with blood obtained from control subjects, there was a synergistic inhibition of cytotoxic T lymphocyte activity when the cells were cultured in a combination of pravastatin and cyclosporine (20.3% mean cytotoxicity of target cells vs 41.4% in the control group, p < 0.01). CONCLUSIONS: Pravastatin exerts an immunosuppressive effect in heart transplant recipients as expressed by a reduction in rejection and natural killer cell cytotoxicity. Pravastatin and cyclosporine act synergistically to reduce cytotoxic T lymphocyte activity. This synergistic effect of pravastatin and cyclosporine may explain why this immunosuppressive effect is unique to transplant recipients.
PMID: 9588577 [PubMed - indexed for MEDLINE]
1: Drugs. 2002;62(15):2185-91.
HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant
rejection.
Raggatt LJ, Partridge NC.
Department of Physiology and Biophysics, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854,
USA.
The benefit of HMG-CoA reductase inhibitors (statins) to the cardiovascular system is now well established and these drugs are being used extensively to treat hypercholesterolaemia clinically. However, as clinical outcomes become available it appears that statins are proving more beneficial than expected and thus it is being proposed that the actions of statins go beyond their ability to lower serum cholesterol levels. The report that statins can interact directly with lymphocyte function-associated antigen (LFA)-1 and prevent it engaging with the intracellular adhesion molecule (ICAM)-1 receptor on T cells is a novel mechanism of statin action and provides convincing evidence that these compounds can regulate biological systems other than by the cholesterol synthesis pathway. Immunosuppression to prevent organ transplant rejection is one application for which statins are currently being assessed. The clinical evidence is conflicting and does not convincingly reflect whether statins are beneficial as immunomodulators. However, in vivo studies investigating the cellular actions of statins have identified two mechanisms by which statins can potentially modulate an in vivo immune response. Firstly, statins regulate inducible class II major histocompatibility complex (MHC) expression on macrophages and endothelial cells. Secondly, statins can inhibit LFA-1 adhesion to ICAM-1 and thus regulate T cell activation. These findings suggest that statins have the potential to regulate an immune response in vivo and that more investigation is essential in order to explain the opposing clinical data.
PMID: 12381218 [PubMed - indexed for MEDLINE]
1: Atheroscler Suppl. 2002 May;3(1):17-20.
Immunosuppressive effects of statins.
Mach F.
Medicine Department, Cardiology Division, Foundation for Medical Research, Geneva
Medical School, University Hospital, 64 Avenue Roseraie, 1211 Geneva,
Switzerland.
3-Hydroxy-3-methhylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are effective lipid lowering agents, extensively used in medical practice [Circulation 2000;101:207; J Am Med Assoc 2000;283:2935]. Statins have never been shown to be involved in the immune response, although reports have suggested a better outcome of cardiac transplantation in patients under pravastatin therapy [New Engl J Med 1995;333:621; Circulation 1997;96:1398]. Major histocompatibility complex class II (MHC class II) molecules are directly involved in the activation of T lymphocytes and in the control of the immune response. Whereas only a limited number of specialized cell types express MHC-II constitutively, numerous other cells become MHC-II positive upon induction by interferon-gamma (IFN-gamma) [Annu Rev Immunol 1996;14:301]. This complex regulation is under the control of the transactivator CIITA [Science 1994;265:106]. Recently, we demonstrated that statins act as direct inhibitors of induction of MHC-II expression by IFN-gamma and thus as repressors of MHC-II-mediated T cell activation [Nat Med 2000;6:1399; Swiss Med Wkly 2001;131:41]. This effect of statins is due to inhibition of the inducible promoter IV of the transactivator CIITA. Interestingly, this inhibition is specific for inducible MHC-II expression and does not concern constitutive expression of CIITA and MHC-II. In repressing induction of MHC-II, and subsequent T lymphocyte activation, statins therefore behave as a novel type of immunomodulator. This unexpected effect provides a scientific rationale for suggesting the use of statins as novel immunosuppressors, not only in organ transplantation but in numerous other pathologies as well.
PMID: 12044581 [PubMed - indexed for MEDLINE]
1: Swiss Med Wkly. 2001 Jan 27;131(3-4):41-6.
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class
II expression in human vascular endothelial cells.
Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F.
Cardiology Division, Department of Medicine, University Hospital, Geneva Medical
School, Foundation for Medical Research, Geneva, Switzerland.
HMG-CoA reductase inhibitors, or statins, are lipid-lowering agents that have been shown to effectively decrease severe rejection periods and development of transplant coronary artery disease after heart transplantation. Precise regulation of major histocompatibility complex class II (MHC class II) gene expression plays a pivotal role in control of the immune response after transplantation. The aim of this study was to evaluate the potential role of HMG-CoA reductase inhibitors in regulating the immune response. We have examined the effects of simvastatin on MHC class II expression in primary human endothelial cells. Using RNAse protection assay and flow cytometry, we observed that simvastatin dose-dependently reduced interferon-gamma (IFN-gamma) induced MHC class II expression (mRNA and protein). In contrast, simvastatin did not affect the expression of MHC class I, pointing to specific actions in the MHC class II signalling cascade. The transcriptional coactivator CIITA is the general regulator of both constitutive and inducible MHC class II expression. After stimulation with IFN-gamma, the CIITA gene is selectively activated via one (promotor IV) of its four promoters. Interestingly, mRNA levels of CIITA were decreased after treatment with simvastatin. In addition, using transient transfections of promoter-reporter constructs we observed that the activity of CIITA promoter IV was decreased by simvastatin. In conclusion, simvastatin selectively decreases IFN-gamma-induced MHC class II expression in human primary endothelial cells through actions on the CIITA promoter IV. Thus, the beneficial effects of statins reported after heart transplantation may result from this immunosuppressive action, suggesting possible therapeutic use for other immunological disorders as well.
PMID: 11219190 [PubMed - indexed for MEDLINE]
1: Cancer Immunol Immunother. 2009 Mar;58(3):461-7. Epub 2008 Jun 4.
Potential immunologic effects of statins in cancer following transplantation.
Fildes JE, Shaw SM, Williams SG, Yonan N.
The Transplant Centre, University Hospital of South Manchester NHS Foundation
Trust, Wythenshawe Hospital, Manchester, UK. james.fildes@manchester.ac.uk
3-hydroxy-3-methyglutaryl CoA reductase inhibitors (statins) are frequently used following organ transplantation and have well reported pleiotropic effects, including immunomodulation, which may be of benefit in preventing graft rejection. However, the immunomodulatory effects of statins on cell transformation and malignancy, combined with the immunologic processes and administration of immunosuppression are almost completely unknown. The administration of immunosuppression is well recognised as the main cause of cancer following transplantation, so the addition of an immunomodulatory agent should be associated with an increased incidence of cancer, as immune surveillance and response may be suppressed, allowing cellular transformation and proliferation combined with lack of recognition to occur. This hypothetical review attempts to delineate the mode of action of statins in terms of pro/anti-carcinogenic mechanisms, while considering graft rejection and the presence of immunosuppression.
PMID: 18523769 [PubMed - indexed for MEDLINE]
1: J Heart Lung Transplant. 1998 Apr;17(4):335-40.
The inhibitory effects of pravastatin on natural killer cell activity in vivo and
on cytotoxic T lymphocyte activity in vitro.
Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Terasaki PI,
Kobashigawa JA.
Division of Nephrology, University of California, Davis, School of Medicine,
Sacramento, USA.
BACKGROUND: We have reported that heart transplant recipients treated with pravastatin demonstrate decreases in the incidence of clinically severe acute rejection episodes, the incidence and progression of transplant coronary vasculopathy, and natural killer cytotoxicity. These patients also exhibited a significant improvement in 1-year allograft survival. Because of these clinical findings suggesting an immunosuppressive effect of pravastatin unique to transplant recipients and the unclear role of natural killer cells in allograft rejection, we postulated that pravastatin may exert its immunomodulatory effect by acting with cyclosporine to alter T lymphocyte function. METHODS: Twenty patients randomized into an ongoing trial of pravastatin after heart transplantation were monitored serially for natural killer cell cytotoxicity. In a separate experiment, lymphocytes isolated from normal volunteers were treated with various combinations of pravastatin and cyclosporine and tested for cytotoxic T lymphocyte toxicity in a one-way mixed lymphocyte reaction. RESULTS: Pravastatin-treated heart transplant recipients exhibited a decrease in natural killer cell cytotoxicity (9.8% mean natural killer cell cytotoxicity vs 22.1% in the control group, p < 0.01). In the one-way mixed lymphocyte reaction with blood obtained from control subjects, there was a synergistic inhibition of cytotoxic T lymphocyte activity when the cells were cultured in a combination of pravastatin and cyclosporine (20.3% mean cytotoxicity of target cells vs 41.4% in the control group, p < 0.01). CONCLUSIONS: Pravastatin exerts an immunosuppressive effect in heart transplant recipients as expressed by a reduction in rejection and natural killer cell cytotoxicity. Pravastatin and cyclosporine act synergistically to reduce cytotoxic T lymphocyte activity. This synergistic effect of pravastatin and cyclosporine may explain why this immunosuppressive effect is unique to transplant recipients.
PMID: 9588577 [PubMed - indexed for MEDLINE]
1: Drugs. 2002;62(15):2185-91.
HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant
rejection.
Raggatt LJ, Partridge NC.
Department of Physiology and Biophysics, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854,
USA.
The benefit of HMG-CoA reductase inhibitors (statins) to the cardiovascular system is now well established and these drugs are being used extensively to treat hypercholesterolaemia clinically. However, as clinical outcomes become available it appears that statins are proving more beneficial than expected and thus it is being proposed that the actions of statins go beyond their ability to lower serum cholesterol levels. The report that statins can interact directly with lymphocyte function-associated antigen (LFA)-1 and prevent it engaging with the intracellular adhesion molecule (ICAM)-1 receptor on T cells is a novel mechanism of statin action and provides convincing evidence that these compounds can regulate biological systems other than by the cholesterol synthesis pathway. Immunosuppression to prevent organ transplant rejection is one application for which statins are currently being assessed. The clinical evidence is conflicting and does not convincingly reflect whether statins are beneficial as immunomodulators. However, in vivo studies investigating the cellular actions of statins have identified two mechanisms by which statins can potentially modulate an in vivo immune response. Firstly, statins regulate inducible class II major histocompatibility complex (MHC) expression on macrophages and endothelial cells. Secondly, statins can inhibit LFA-1 adhesion to ICAM-1 and thus regulate T cell activation. These findings suggest that statins have the potential to regulate an immune response in vivo and that more investigation is essential in order to explain the opposing clinical data.
PMID: 12381218 [PubMed - indexed for MEDLINE]
1: Atheroscler Suppl. 2002 May;3(1):17-20.
Immunosuppressive effects of statins.
Mach F.
Medicine Department, Cardiology Division, Foundation for Medical Research, Geneva
Medical School, University Hospital, 64 Avenue Roseraie, 1211 Geneva,
Switzerland.
3-Hydroxy-3-methhylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are effective lipid lowering agents, extensively used in medical practice [Circulation 2000;101:207; J Am Med Assoc 2000;283:2935]. Statins have never been shown to be involved in the immune response, although reports have suggested a better outcome of cardiac transplantation in patients under pravastatin therapy [New Engl J Med 1995;333:621; Circulation 1997;96:1398]. Major histocompatibility complex class II (MHC class II) molecules are directly involved in the activation of T lymphocytes and in the control of the immune response. Whereas only a limited number of specialized cell types express MHC-II constitutively, numerous other cells become MHC-II positive upon induction by interferon-gamma (IFN-gamma) [Annu Rev Immunol 1996;14:301]. This complex regulation is under the control of the transactivator CIITA [Science 1994;265:106]. Recently, we demonstrated that statins act as direct inhibitors of induction of MHC-II expression by IFN-gamma and thus as repressors of MHC-II-mediated T cell activation [Nat Med 2000;6:1399; Swiss Med Wkly 2001;131:41]. This effect of statins is due to inhibition of the inducible promoter IV of the transactivator CIITA. Interestingly, this inhibition is specific for inducible MHC-II expression and does not concern constitutive expression of CIITA and MHC-II. In repressing induction of MHC-II, and subsequent T lymphocyte activation, statins therefore behave as a novel type of immunomodulator. This unexpected effect provides a scientific rationale for suggesting the use of statins as novel immunosuppressors, not only in organ transplantation but in numerous other pathologies as well.
PMID: 12044581 [PubMed - indexed for MEDLINE]
1: Swiss Med Wkly. 2001 Jan 27;131(3-4):41-6.
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class
II expression in human vascular endothelial cells.
Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F.
Cardiology Division, Department of Medicine, University Hospital, Geneva Medical
School, Foundation for Medical Research, Geneva, Switzerland.
HMG-CoA reductase inhibitors, or statins, are lipid-lowering agents that have been shown to effectively decrease severe rejection periods and development of transplant coronary artery disease after heart transplantation. Precise regulation of major histocompatibility complex class II (MHC class II) gene expression plays a pivotal role in control of the immune response after transplantation. The aim of this study was to evaluate the potential role of HMG-CoA reductase inhibitors in regulating the immune response. We have examined the effects of simvastatin on MHC class II expression in primary human endothelial cells. Using RNAse protection assay and flow cytometry, we observed that simvastatin dose-dependently reduced interferon-gamma (IFN-gamma) induced MHC class II expression (mRNA and protein). In contrast, simvastatin did not affect the expression of MHC class I, pointing to specific actions in the MHC class II signalling cascade. The transcriptional coactivator CIITA is the general regulator of both constitutive and inducible MHC class II expression. After stimulation with IFN-gamma, the CIITA gene is selectively activated via one (promotor IV) of its four promoters. Interestingly, mRNA levels of CIITA were decreased after treatment with simvastatin. In addition, using transient transfections of promoter-reporter constructs we observed that the activity of CIITA promoter IV was decreased by simvastatin. In conclusion, simvastatin selectively decreases IFN-gamma-induced MHC class II expression in human primary endothelial cells through actions on the CIITA promoter IV. Thus, the beneficial effects of statins reported after heart transplantation may result from this immunosuppressive action, suggesting possible therapeutic use for other immunological disorders as well.
PMID: 11219190 [PubMed - indexed for MEDLINE]
1: Cancer Immunol Immunother. 2009 Mar;58(3):461-7. Epub 2008 Jun 4.
Potential immunologic effects of statins in cancer following transplantation.
Fildes JE, Shaw SM, Williams SG, Yonan N.
The Transplant Centre, University Hospital of South Manchester NHS Foundation
Trust, Wythenshawe Hospital, Manchester, UK. james.fildes@manchester.ac.uk
3-hydroxy-3-methyglutaryl CoA reductase inhibitors (statins) are frequently used following organ transplantation and have well reported pleiotropic effects, including immunomodulation, which may be of benefit in preventing graft rejection. However, the immunomodulatory effects of statins on cell transformation and malignancy, combined with the immunologic processes and administration of immunosuppression are almost completely unknown. The administration of immunosuppression is well recognised as the main cause of cancer following transplantation, so the addition of an immunomodulatory agent should be associated with an increased incidence of cancer, as immune surveillance and response may be suppressed, allowing cellular transformation and proliferation combined with lack of recognition to occur. This hypothetical review attempts to delineate the mode of action of statins in terms of pro/anti-carcinogenic mechanisms, while considering graft rejection and the presence of immunosuppression.
PMID: 18523769 [PubMed - indexed for MEDLINE]
More Evidence That Titles Do Not an Expert Make: Statins
I hate reading stuff like this because after all I started out wanting to make some good pills for peoples' health. More often than I like to read, these companies pawn useless stuff that causes another disease. It's cut and paste from http://www.hoptechno.com/statinsheets.htm
If the authors contact me, I'll gladly remove it but I can simply link to it. Perhaps the intentions were good in the beginning, but the disease misunderstood, and the outcome terrible, all the while the corporate fat cats lined their pockets at the expense of peoples' arteries. To me, that is more morbid and disturbing than a horror movie but I am sure plenty of people will come to the aid of the statin camp. The next post I have will be even more mind boggling.
"Cancer, Longevity and Statins
Do statins cause cancer or affect longevity?
Editor's note: The following are a sample of results of a search on the safety of statins (Cholesterol lowering drugs; e.g. Lipitor, Mevacor, Pravachol, Zocor).
It appears that:
1. there is a danger that statins cause cancer in humans
2. death rates in the population have not been reduced as a result of statin use
3. prescribing sheets show that statins cause liver cancer in animals.
Cancer: Source - Journal of the American Medical Association (JAMA) January 1996 The following is an extract.
Carcinogenicity of lipid-lowering drugs.
Newman TB, Hulley SB.
Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, USA.
OBJECTIVE--To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs. DATA SOURCES--Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts. STUDY SAMPLE--We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as "hypolipidemics." For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans. DATA SYNTHESIS--All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans. In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up.
CONCLUSIONS--Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.
Death Rate. Source: http://www.drugintel.com/drugs/statins/statins_critical_review.htm - This link was taken down.
Besides cancer, the other side effects of statins listed were incomplete, and should have included constipation, myalgia, myopathy, polyneuropathy, liver and kidney damage, congestive heart failure and amnesia. Side-effects are usually said to affect 2-6% of patients. In fact, a recent meta-analysis noted side-effects in 20% of patients above the placebo rate (65% vs. 45%), and no change whatever in the all-cause death rate for atorvastatin (Lipitor). [8] The PROSPER trial on pravastatin (Pravachol) showed no change in the all-cause death rate, and increased cancer and stroke rates. [9] Statins are commonly used at a dose to lower TC to <160 mg/dL, a level noted in the report of a NHLBI conference to be associated with higher cancer rates.[10]
Footnotes:
[8] Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients. Am J Cardiol 2003;92:670-6.
[9] Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-30.
[10] Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992:86:1046-60.
Death Rate: Source: Archives of Internal Medicine Vol. 153 No. 9, May 10, 1993 Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data http://archinte.ama-assn.org/cgi/content/abstract/153/9/1065
Conclusion: Physicians should be cautious about initiating cholesterol-lowering treatment in men and women above 65 to 70 years of age. Only randomized clinical trials in older people can settle the debate over the efficacy and cost-effectiveness of lipid-lowering interventions for reducing mortality and morbidity in this population.
The relationship between total cholesterol level and all-cause mortality was positive (ie, higher cholesterol level associated with higher mortality) at age 40 years, negative at age 80 years, and negligible at ages 50 to 70 years. The relationship with CHD mortality was significantly positive at ages 40, 50, and 60 years but attenuated with age until the relationship was positive, but not significant, at age 70 years and negative, but not significant, at age 80 years. Results for the relationship between low-density lipoprotein cholesterol and high-density lipoprotein cholesterol and mortality help explain these findings. Non-CHD mortality was significantly negatively related to cholesterol level for ages 50 years and above. [Ed: - low cholesterol = higher non-chd mortality; high cholesterol = lower; CHD = Coronary Heart Disease]
Prescribing sheets published by manufacturers of statin drugs (Oct 2005): [ALL of them mentioned liver cancer as a side effect]
Lipitor: In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a rhabdomyosarcoma and, in another, there was a fibrosarcoma. This dose represents a plasma AUC (0-24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose. A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver adenomas in high-dose males and liver carcinomas in highdose females. These findings occurred at plasma AUC (0-24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.
Mevacor: In a 24-month carcinogenicity study in rats, there was a positive dose response relationship for hepatocellular carcinogenicity in males at drug exposures between 2-7 times that of human exposure at 80 mg/day (doses in rats were 5, 30 and 180 mg/kg/day).
Pravachol: Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year study in rats fed pravastatin at doses of 10, 30, or 100 mg/kg body weight, there was an increased incidence of hepatocellular carcinomas in males at the highest dose (p<0.01). These effects in rats were observed at approximately 12 times the human dose (HD) of 80 mg, based on body surface area mg/m2 and at approximately 4 times the human dose, based on AUC. In a 2-year study in mice fed pravastatin at doses of 250 and 500 mg/kg/day, there was an increased incidence of hepatocellular carcinomas in males and females at both 250 and 500 mg/kg/day (p<0.0001). At these doses, lung adenomas in females were increased (p=0.013). These effects in mice were observed at approximately 15 times (250 mg/kg/day) and 23 times (500 mg/kg/day) the human dose of 80 mg, based on AUC. In another 2-year study in mice with doses up to 100 mg/kg/day (producing drug exposures approximately 2 times the human dose of 80 mg, based on AUC), there were no drug-induced tumors. No evidence of mutagenicity was observed in vitro, with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests, using mutant strains of Salmonella typhimurium or Escherichia coli ; a forward mutation assay in L5178Y TK +/- mouse lymphoma cells; a chromosomal aberration test in hamster cells; and a gene conversion assay using Saccharomyces cerevisiae. In addition, there was no evidence of mutagenicity in either a dominant lethal test in mice or a micronucleus test in mice.
Zocor: In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80-mg oral dose. Liver carcinomas were significantly increased in high-dose females and midand high-dose males with a maximum incidence of 90% in males. The incidence of adenomas of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high-dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day. In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC). In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular adenomas in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC). A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced hepatocellular adenomas and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell adenomas were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other HMG-CoA reductase inhibitors. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose. No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in ZOCOR® (simvastatin) 9556649 14 an in vitro alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an in vitro chromosome aberration study in CHO cells, or an in vivo chromosomal aberration assay in mouse bone marrow.
Crestor: (Jan 2006) In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses. In a 107-week carcinogenicity study in mice given 10, 60, 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses. Rosuvastatin was not mutagenic or clastogenic with or without me
Effect of Different Antilipidemic Agents and Diets on Mortality
A Systematic Review
Marco Studer, MD; Matthias Briel, MD; Bernd Leimenstoll, MD; Tracy R. Glass, MSc; Heiner C. Bucher, MD, MPH
Arch Intern Med. 2005;165:725-730.
Background Guidelines for the prevention and treatment of hyperlipidemia are often based on trials using combined clinical end points. Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data.
Methods We conducted a systematic search of randomized controlled trials published up to June 2003, comparing any lipid-lowering intervention with placebo or usual diet with respect to mortality. Outcome measures were mortality from all, cardiac, and noncardiovascular causes.
Results A total of 97 studies met eligibility criteria, with 137 140 individuals in intervention and 138 976 individuals in control groups. Compared with control groups, risk ratios for overall mortality were 0.87 for statins (95% confidence interval [CI], 0.81-0.94), 1.00 for fibrates (95% CI, 0.91-1.11), 0.84 for resins (95% CI, 0.66-1.08), 0.96 for niacin (95% CI, 0.86-1.08), 0.77 for n-3 fatty acids (95% CI, 0.63-0.94), and 0.97 for diet (95% CI, 0.91-1.04). Compared with control groups, risk ratios for cardiac mortality indicated benefit from statins (0.78; 95% CI, 0.72-0.84), resins (0.70; 95% CI, 0.50-0.99) and n-3 fatty acids (0.68; 95% CI, 0.52-0.90). Risk ratios for noncardiovascular mortality of any intervention indicated no association when compared with control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI, 1.01-1.27).
Conclusions Statins and n-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality. Any potential reduction in cardiac mortality from fibrates is offset by an increased risk of death from noncardiovascular causes.
Author Affiliations: Basel Institute for Clinical Epidemiology (Drs Studer, Briel, and Bucher and Ms Glass) and Department of Internal Medicine (Drs Studer and Leimenstoll), University Hospital Basel, Basel, Switzerland. (http://archinte.ama-assn.org/cgi/content/abstract/165/7/725)
An article on 2/19/8 from Wall Street Journal begins: COGNITIVE SIDE EFFECTS like memory loss and fuzzy thinking aren't listed on the patient information sheet for Lipitor, the popular cholesterol-lowering drug. But some doctors are voicing concerns that in a small portion of patients, statins like Lipitor may be helping hearts but hurting minds.
"This drug makes women stupid," Orli Etingin, vice chairman of medicine at New York Presbyterian Hospital, declared at a recent luncheon discussion sponsored by Project A.L.S. to raise awareness of gender issues and the brain. Dr. Etingin, who is also founder and director of the Iris Cantor Women's Health Center in New York, told of a typical patient in her 40s, unable to concentrate or recall words. Tests found nothing amiss, but when the woman stopped taking Lipitor, the symptoms vanished. When she resumed taking Lipitor, they returned.
"I've seen this in maybe two dozen patients," Dr. Etingin said later, adding that they did better on other statins. "This is just observational, of course. We really need more studies, particularly on cognitive effects and women."
Comments from visitors:
I was prescribed Mevacor about 20 years ago and became so incapacitated with muscle pain I had to seek medical attention. I was taken off the Mevacor and put on another, I can't remember which at this time, but over 20 years, I have been prescribed every statin available, the last was Crestor, which I took for 3 days and then had a heart attack. Before that, however, I was prescribed Tricor and my kidneys stopped after the 3rd dose and I became extremely ill. Then came the Crestor and the heart attack. For twenty years I have suffered from these muscular pains and when I expressed thoughts that they came from the cholesteral drug I was taking, they just gave me another. After my heart surgery and diagnosis of LAD, my surgeon, Dr. Rosenthal, told me to never take statins again; however, my cardiologist wanted me to try again and I refused and left the office no longer his patient. It has been two years since I have taken a cholesteral lowering drug and my cholesteral is now the lowest it has been since I first began statin therapy. (4/2/06)
My husband died last August 2005 of advanced liver cancer (hepatocellular carcinoma). He tested negative for hepatitis and cirrhosis as the common causes of liver cancer. Nothing ever was said about the lovastatin (mevacor) that he was on since 2003 when he had a mild heart attack. A friend (non-M.D.)mentioned the statin probably caused the cancer. Now, reading your research study results about mevacor and seeing the exact cancer that my husband had, I am wondering if it WAS the mevacor that caused the HCC. WHY was he not more closely monitored? I assume he wasn't since, by the time it was accidentally discovered, his cancer was too advanced to do anything. What can we do as laymen to protect ourselves if our physicians are not protecting us? His cardiologist, by the way, attended him even after his cancer was diagnosed and did not stop his medications. His primary doctor prescribed pain killers for 3 months for his pain and did not order any tests. Another doctor (when his primary was not available) ordered the CT-scan and that's when his cancer was discovered. He died 3 months later. We are with Kaiser - however, is the problem still there regardless of whether you are with an HMO or not? I really would like to know what our options are; what we can do, if anything. (5/5/06)
Article Index
Planning a Wedding? Click Here. | Manage your neighborhood Book Club. | Chinese Medicine and Art. | Census data about you. | US Directory of Vendors
©1986-2009 Hopkins Technology, LLC "
If the authors contact me, I'll gladly remove it but I can simply link to it. Perhaps the intentions were good in the beginning, but the disease misunderstood, and the outcome terrible, all the while the corporate fat cats lined their pockets at the expense of peoples' arteries. To me, that is more morbid and disturbing than a horror movie but I am sure plenty of people will come to the aid of the statin camp. The next post I have will be even more mind boggling.
"Cancer, Longevity and Statins
Do statins cause cancer or affect longevity?
Editor's note: The following are a sample of results of a search on the safety of statins (Cholesterol lowering drugs; e.g. Lipitor, Mevacor, Pravachol, Zocor).
It appears that:
1. there is a danger that statins cause cancer in humans
2. death rates in the population have not been reduced as a result of statin use
3. prescribing sheets show that statins cause liver cancer in animals.
Cancer: Source - Journal of the American Medical Association (JAMA) January 1996 The following is an extract.
Carcinogenicity of lipid-lowering drugs.
Newman TB, Hulley SB.
Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, USA.
OBJECTIVE--To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs. DATA SOURCES--Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts. STUDY SAMPLE--We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as "hypolipidemics." For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans. DATA SYNTHESIS--All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans. In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up.
CONCLUSIONS--Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.
Death Rate. Source: http://www.drugintel.com/drugs/statins/statins_critical_review.htm - This link was taken down.
Besides cancer, the other side effects of statins listed were incomplete, and should have included constipation, myalgia, myopathy, polyneuropathy, liver and kidney damage, congestive heart failure and amnesia. Side-effects are usually said to affect 2-6% of patients. In fact, a recent meta-analysis noted side-effects in 20% of patients above the placebo rate (65% vs. 45%), and no change whatever in the all-cause death rate for atorvastatin (Lipitor). [8] The PROSPER trial on pravastatin (Pravachol) showed no change in the all-cause death rate, and increased cancer and stroke rates. [9] Statins are commonly used at a dose to lower TC to <160 mg/dL, a level noted in the report of a NHLBI conference to be associated with higher cancer rates.[10]
Footnotes:
[8] Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients. Am J Cardiol 2003;92:670-6.
[9] Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-30.
[10] Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992:86:1046-60.
Death Rate: Source: Archives of Internal Medicine Vol. 153 No. 9, May 10, 1993 Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data http://archinte.ama-assn.org/cgi/content/abstract/153/9/1065
Conclusion: Physicians should be cautious about initiating cholesterol-lowering treatment in men and women above 65 to 70 years of age. Only randomized clinical trials in older people can settle the debate over the efficacy and cost-effectiveness of lipid-lowering interventions for reducing mortality and morbidity in this population.
The relationship between total cholesterol level and all-cause mortality was positive (ie, higher cholesterol level associated with higher mortality) at age 40 years, negative at age 80 years, and negligible at ages 50 to 70 years. The relationship with CHD mortality was significantly positive at ages 40, 50, and 60 years but attenuated with age until the relationship was positive, but not significant, at age 70 years and negative, but not significant, at age 80 years. Results for the relationship between low-density lipoprotein cholesterol and high-density lipoprotein cholesterol and mortality help explain these findings. Non-CHD mortality was significantly negatively related to cholesterol level for ages 50 years and above. [Ed: - low cholesterol = higher non-chd mortality; high cholesterol = lower; CHD = Coronary Heart Disease]
Prescribing sheets published by manufacturers of statin drugs (Oct 2005): [ALL of them mentioned liver cancer as a side effect]
Lipitor: In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a rhabdomyosarcoma and, in another, there was a fibrosarcoma. This dose represents a plasma AUC (0-24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose. A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver adenomas in high-dose males and liver carcinomas in highdose females. These findings occurred at plasma AUC (0-24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.
Mevacor: In a 24-month carcinogenicity study in rats, there was a positive dose response relationship for hepatocellular carcinogenicity in males at drug exposures between 2-7 times that of human exposure at 80 mg/day (doses in rats were 5, 30 and 180 mg/kg/day).
Pravachol: Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year study in rats fed pravastatin at doses of 10, 30, or 100 mg/kg body weight, there was an increased incidence of hepatocellular carcinomas in males at the highest dose (p<0.01). These effects in rats were observed at approximately 12 times the human dose (HD) of 80 mg, based on body surface area mg/m2 and at approximately 4 times the human dose, based on AUC. In a 2-year study in mice fed pravastatin at doses of 250 and 500 mg/kg/day, there was an increased incidence of hepatocellular carcinomas in males and females at both 250 and 500 mg/kg/day (p<0.0001). At these doses, lung adenomas in females were increased (p=0.013). These effects in mice were observed at approximately 15 times (250 mg/kg/day) and 23 times (500 mg/kg/day) the human dose of 80 mg, based on AUC. In another 2-year study in mice with doses up to 100 mg/kg/day (producing drug exposures approximately 2 times the human dose of 80 mg, based on AUC), there were no drug-induced tumors. No evidence of mutagenicity was observed in vitro, with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests, using mutant strains of Salmonella typhimurium or Escherichia coli ; a forward mutation assay in L5178Y TK +/- mouse lymphoma cells; a chromosomal aberration test in hamster cells; and a gene conversion assay using Saccharomyces cerevisiae. In addition, there was no evidence of mutagenicity in either a dominant lethal test in mice or a micronucleus test in mice.
Zocor: In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80-mg oral dose. Liver carcinomas were significantly increased in high-dose females and midand high-dose males with a maximum incidence of 90% in males. The incidence of adenomas of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high-dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day. In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC). In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular adenomas in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC). A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced hepatocellular adenomas and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell adenomas were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other HMG-CoA reductase inhibitors. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose. No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in ZOCOR® (simvastatin) 9556649 14 an in vitro alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an in vitro chromosome aberration study in CHO cells, or an in vivo chromosomal aberration assay in mouse bone marrow.
Crestor: (Jan 2006) In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses. In a 107-week carcinogenicity study in mice given 10, 60, 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses. Rosuvastatin was not mutagenic or clastogenic with or without me
Effect of Different Antilipidemic Agents and Diets on Mortality
A Systematic Review
Marco Studer, MD; Matthias Briel, MD; Bernd Leimenstoll, MD; Tracy R. Glass, MSc; Heiner C. Bucher, MD, MPH
Arch Intern Med. 2005;165:725-730.
Background Guidelines for the prevention and treatment of hyperlipidemia are often based on trials using combined clinical end points. Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data.
Methods We conducted a systematic search of randomized controlled trials published up to June 2003, comparing any lipid-lowering intervention with placebo or usual diet with respect to mortality. Outcome measures were mortality from all, cardiac, and noncardiovascular causes.
Results A total of 97 studies met eligibility criteria, with 137 140 individuals in intervention and 138 976 individuals in control groups. Compared with control groups, risk ratios for overall mortality were 0.87 for statins (95% confidence interval [CI], 0.81-0.94), 1.00 for fibrates (95% CI, 0.91-1.11), 0.84 for resins (95% CI, 0.66-1.08), 0.96 for niacin (95% CI, 0.86-1.08), 0.77 for n-3 fatty acids (95% CI, 0.63-0.94), and 0.97 for diet (95% CI, 0.91-1.04). Compared with control groups, risk ratios for cardiac mortality indicated benefit from statins (0.78; 95% CI, 0.72-0.84), resins (0.70; 95% CI, 0.50-0.99) and n-3 fatty acids (0.68; 95% CI, 0.52-0.90). Risk ratios for noncardiovascular mortality of any intervention indicated no association when compared with control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI, 1.01-1.27).
Conclusions Statins and n-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality. Any potential reduction in cardiac mortality from fibrates is offset by an increased risk of death from noncardiovascular causes.
Author Affiliations: Basel Institute for Clinical Epidemiology (Drs Studer, Briel, and Bucher and Ms Glass) and Department of Internal Medicine (Drs Studer and Leimenstoll), University Hospital Basel, Basel, Switzerland. (http://archinte.ama-assn.org/cgi/content/abstract/165/7/725)
An article on 2/19/8 from Wall Street Journal begins: COGNITIVE SIDE EFFECTS like memory loss and fuzzy thinking aren't listed on the patient information sheet for Lipitor, the popular cholesterol-lowering drug. But some doctors are voicing concerns that in a small portion of patients, statins like Lipitor may be helping hearts but hurting minds.
"This drug makes women stupid," Orli Etingin, vice chairman of medicine at New York Presbyterian Hospital, declared at a recent luncheon discussion sponsored by Project A.L.S. to raise awareness of gender issues and the brain. Dr. Etingin, who is also founder and director of the Iris Cantor Women's Health Center in New York, told of a typical patient in her 40s, unable to concentrate or recall words. Tests found nothing amiss, but when the woman stopped taking Lipitor, the symptoms vanished. When she resumed taking Lipitor, they returned.
"I've seen this in maybe two dozen patients," Dr. Etingin said later, adding that they did better on other statins. "This is just observational, of course. We really need more studies, particularly on cognitive effects and women."
Comments from visitors:
I was prescribed Mevacor about 20 years ago and became so incapacitated with muscle pain I had to seek medical attention. I was taken off the Mevacor and put on another, I can't remember which at this time, but over 20 years, I have been prescribed every statin available, the last was Crestor, which I took for 3 days and then had a heart attack. Before that, however, I was prescribed Tricor and my kidneys stopped after the 3rd dose and I became extremely ill. Then came the Crestor and the heart attack. For twenty years I have suffered from these muscular pains and when I expressed thoughts that they came from the cholesteral drug I was taking, they just gave me another. After my heart surgery and diagnosis of LAD, my surgeon, Dr. Rosenthal, told me to never take statins again; however, my cardiologist wanted me to try again and I refused and left the office no longer his patient. It has been two years since I have taken a cholesteral lowering drug and my cholesteral is now the lowest it has been since I first began statin therapy. (4/2/06)
My husband died last August 2005 of advanced liver cancer (hepatocellular carcinoma). He tested negative for hepatitis and cirrhosis as the common causes of liver cancer. Nothing ever was said about the lovastatin (mevacor) that he was on since 2003 when he had a mild heart attack. A friend (non-M.D.)mentioned the statin probably caused the cancer. Now, reading your research study results about mevacor and seeing the exact cancer that my husband had, I am wondering if it WAS the mevacor that caused the HCC. WHY was he not more closely monitored? I assume he wasn't since, by the time it was accidentally discovered, his cancer was too advanced to do anything. What can we do as laymen to protect ourselves if our physicians are not protecting us? His cardiologist, by the way, attended him even after his cancer was diagnosed and did not stop his medications. His primary doctor prescribed pain killers for 3 months for his pain and did not order any tests. Another doctor (when his primary was not available) ordered the CT-scan and that's when his cancer was discovered. He died 3 months later. We are with Kaiser - however, is the problem still there regardless of whether you are with an HMO or not? I really would like to know what our options are; what we can do, if anything. (5/5/06)
Article Index
Planning a Wedding? Click Here. | Manage your neighborhood Book Club. | Chinese Medicine and Art. | Census data about you. | US Directory of Vendors
©1986-2009 Hopkins Technology, LLC "
Saturday, August 15, 2009
Get your vitamins?
Of course get your vitamins.
As I get off of work, which currently preoccupies me with the prevention and treatment of diabetes mellitus naturally, I still find that we could all benefit from nutritional information.
From the angle I work, I contribute the fact that we are basically engines that require carbon fuel, water soluble elements, water, a little bit of very specific oils, a tiny bit of oil soluble elements, and air to work. Our physiques are sophisticated carbon engines that require more than just liquid alkanes and oxygen for combustion. If our fuels are tainted, even just slightly, our systems corrode over time. Every mechanic knows this intuitively, and all doctors should find this common sense too. Yet, they blindly ignore this and go on stubbornly as the face of youth fools them into thinking that old age will provide the same biological resilience as youth. Of course it won't. Not even in the best care will our carriage last much past 100 years old due to a "self-destruct" clock called "telomere." So I encourage all my associates and peers to look into healthy diets and augmenting their regimens with vitamins, minerals, amino acids, and herbal components.
You may or may not get to the century club, but you should get to whatever age you will be in grand and robust health and the fullness of life. To that end, you as a person who values this right should fight all effort to imprison you.
As I get off of work, which currently preoccupies me with the prevention and treatment of diabetes mellitus naturally, I still find that we could all benefit from nutritional information.
From the angle I work, I contribute the fact that we are basically engines that require carbon fuel, water soluble elements, water, a little bit of very specific oils, a tiny bit of oil soluble elements, and air to work. Our physiques are sophisticated carbon engines that require more than just liquid alkanes and oxygen for combustion. If our fuels are tainted, even just slightly, our systems corrode over time. Every mechanic knows this intuitively, and all doctors should find this common sense too. Yet, they blindly ignore this and go on stubbornly as the face of youth fools them into thinking that old age will provide the same biological resilience as youth. Of course it won't. Not even in the best care will our carriage last much past 100 years old due to a "self-destruct" clock called "telomere." So I encourage all my associates and peers to look into healthy diets and augmenting their regimens with vitamins, minerals, amino acids, and herbal components.
You may or may not get to the century club, but you should get to whatever age you will be in grand and robust health and the fullness of life. To that end, you as a person who values this right should fight all effort to imprison you.
Monday, August 10, 2009
Before you reach for that synthetic drug:
Remember that there are those who are sincerely interested in your well-being and would have you maintain your own health in your own hands, at your own control. That is my point and I don't really have any other message to send. Mine is that you can defeat major illness simply and naturally given knowledge revealed by science and the God given pharmacy of nature.
After all, every single synthetic drug owes its existence to Man making a discovery of nature. While I resist entering into political arguments and forays, one fatal chamber of humanity, I do encourage those who may be feeling unwell or who are sick to deeply investigate natural health regimens. Afterall, they are no different than pharmaceuticals. Pharmaceuticals are simply compounds or variations on what is in nature. Pharma Media has lead the majority to believe that pills are different from what is found in Nature.
The Deception uncovered is that everything is molecular in nature, and that a psychological trick has been played upon the public to believe that something that isn't in a pill isn't a molecule. Everything is a molecule. Our entire basis of existence and experience, regardless of whether it is sublime or foul is molecular.
The unfortunate fact is that there are charlatans, there are quacks, there are selfish entrepreneurs with bizarre distraction tactics. You will have to be diligent to see what is true and what is false to maintain your health without paying a Capitalist Cabal massive amounts of your hard earned money to stay well. That is my singular point - that you shouldn't have to make capitalists rich to stay well, because there are gifts of nature and evolution that will do you as well, and if that isn't a noble cause, I don't know what is.
After all, every single synthetic drug owes its existence to Man making a discovery of nature. While I resist entering into political arguments and forays, one fatal chamber of humanity, I do encourage those who may be feeling unwell or who are sick to deeply investigate natural health regimens. Afterall, they are no different than pharmaceuticals. Pharmaceuticals are simply compounds or variations on what is in nature. Pharma Media has lead the majority to believe that pills are different from what is found in Nature.
The Deception uncovered is that everything is molecular in nature, and that a psychological trick has been played upon the public to believe that something that isn't in a pill isn't a molecule. Everything is a molecule. Our entire basis of existence and experience, regardless of whether it is sublime or foul is molecular.
The unfortunate fact is that there are charlatans, there are quacks, there are selfish entrepreneurs with bizarre distraction tactics. You will have to be diligent to see what is true and what is false to maintain your health without paying a Capitalist Cabal massive amounts of your hard earned money to stay well. That is my singular point - that you shouldn't have to make capitalists rich to stay well, because there are gifts of nature and evolution that will do you as well, and if that isn't a noble cause, I don't know what is.
Monday, July 6, 2009
Vitamin C and Thrombosis
It is well known that vWf (von Willebrand factor) is essential for platelet aggregation in clotting. Those individuals deficient in it are somewhat hemophiliac.
It is also known the vWf is exposed and present at sites of endothelial (inner most layer of cells of artery) injury, at which platelets are attracted like iron filings to a magnet. This begins the cascade of thrombosis which is responsible for end-stage ischemic events. This is true whether there is or isn't a large plaque.
It is best not to have a plaque, as this can be a chronic homing beacon for trouble, but it must be remembered that the biochemical cascade is not cholesterol causing a jam in the lumen of the artery (that never happens), but a blood clot.
This may happen with or without a plaque bursting, although plaque burst definitely will expose the subendothelial vWf stuck to collagen that makes platelets stick.
PGI2 inhibits this platelet adhesion extremely effectively. PGI2 is prostacyclin.
Administering supranormal levels of ascorbic acid greatly enhances the levels of prostacyclin production into the bloodstream.
It is also known the vWf is exposed and present at sites of endothelial (inner most layer of cells of artery) injury, at which platelets are attracted like iron filings to a magnet. This begins the cascade of thrombosis which is responsible for end-stage ischemic events. This is true whether there is or isn't a large plaque.
It is best not to have a plaque, as this can be a chronic homing beacon for trouble, but it must be remembered that the biochemical cascade is not cholesterol causing a jam in the lumen of the artery (that never happens), but a blood clot.
This may happen with or without a plaque bursting, although plaque burst definitely will expose the subendothelial vWf stuck to collagen that makes platelets stick.
PGI2 inhibits this platelet adhesion extremely effectively. PGI2 is prostacyclin.
Administering supranormal levels of ascorbic acid greatly enhances the levels of prostacyclin production into the bloodstream.
Sunday, June 21, 2009
The Th1->Th2 Switch in HIV-AIDS Is an Allergy Hypothesis
This Israeli group describes AIDS as the immune response switch to Th2, with overabundant IgE, which then disables Th1 cytotoxic responses.
1: Virus Genes. 2004 Apr;28(3):319-31.
HIV-1 induced AIDS is an allergy and the allergen is the Shed gp120--a review,
hypothesis, and implications.
Becker Y.
Department of Molecular Virology, Faculty of Medicine, The Hebrew University of
Jerusalem, P.O. Box 12272, Jerusalem 91120, Israel. becker@med.huji.ac.il
The possibility that the induction of T helper 2 (Th2) cytokine synthesis and the gradual increase in interleukin 4 (IL-4) and IgE levels during HIV-1 infection are an allergic response to HIV-1 proteins was raised in the author's previous article [Becker, Virus Genes 28, 1-4, 2004]. The present review extends this hypothesis by citing experimental reports which indicate that HIV-1 shed gp120 virions share a striking resemblance with the allergens that bind to IgE molecules bound to Fc epsilon receptor I-positive (Fc epsilon RI) cells (mast cells, basophils, monocytes, and dendritic cells, DC) and then induce them to release and synthesize the IL-4 cytokine. In the earlier review, it was established that the IL-4 cytokine is responsible for the following processes: IgE synthesis by B cells and the inhibition of antiviral IgG synthesis; the inactivation of T helper 1 (Th1) cells; and the inhibition of the antiviral cytotoxic T cell (CTL) response. The binding of the shed gp120 to B cell-bound immunoglobulin (Ig) depletes these cells. Moreover, it was reported that the viral regulatory proteins Tat and Vpr also stimulate IL-4 release from basophils. The mode of action used by HIV-1 gp120 in the induction of IL-4 [Becker, Virus Genes 28, 1-14, 2004] revealed that the viral protein contains a superantigen (SAg) domain that is capable of binding to the V(H)3 domain of IgE and Ig; namely, the shed gp120 protein act as endogenous and environmental allergens that
bind to IgE molecules, which are bound to the Fc epsilon RI receptors on hematopoietic cells. Based on these findings, it is hypothesized that gp120 is an allergen. Consequently, it can be inferred that the active replication of HIV-1 in infected individuals constantly exposes the immune system to an increase in the allergen content until the host immunity is eventually compromised. These finding suggest that HIV-1 engage in a two-pronged attack of the human immune system: it infects Th2 cells, macrophages, and DCs and then replicates at these venues; and the shed gp120 cells cause an allergy. This allergic condition consequently prevents the induction of Th1 cells, cytokine synthesis, and antiviral CTLs that are needed to clear the infecting virus and thus devitalizes the antivirals that are used to treat the virus infection. It was hypothesized [Becker, Virus Genus 28, 1-14, 2004] that the HIV-1 induced allergy can be treated with IL-4 inhibitors or immune response modifiers. A treatment that employs both antivirals and anti-allergen drugs may very well defeat the AIDS syndrome. Another implication of the present hypothesis is the need to improve the viral antigen used for vaccinating healthy individuals against HIV-1 infection. It is thus suggested harmful domains be eliminated from the gp120.
PMID: 15266113 [PubMed - indexed for MEDLINE]
If this is true, there are many things which dampen Th2 and augment Th1 naturally, such as L-theanine, zinc, selenium, and things like citrus:
1: Mediators Inflamm. 2008;2008:496467. Epub 2008 Nov 30.
Citrus/Cydonia comp. can restore the immunological balance in seasonal allergic
rhinitis-related immunological parameters in vitro.
Baars EW, Savelkoul HF.
Department of Healthcare and Nutrition, Louis Bolk Instituut, 3972 LA Driebergen,
The Netherlands. e.baars@louisbolk.nl
In two in vitro studies, we examined the immunological (pathways of the) effects of Citrus/Cydonia comp. from, respectively, a healthy and an allergic donor; peripheral blood mononuclear cells (PBMCs) were isolated out of peripheral blood and analyzed in vitro after polyclonal stimulation of T-cells. The differentiation capacity and the influence with regard to Th1 (IFN-gamma) and Th2 (IL-5) cells were examined. Citrus/Cydonia comp. has a selective effect on the differentiation of T-cells by producing relatively more IL-10 than IL-12. By that, it also seems to have an effect on the induction of regulatory (IL-10 producing) T-cell subsets. It is in vitro capable of neutralizing (to some extent) the changes, characteristic to allergic rhinitis, with regard to the maturation, differentiation, and activity of the immune system. Thus, Citrus/Cydonia comp. can potentially restore the disturbed immune state of rhinitis patients, which essentially could be sufficient to make allergic
symptoms disappear permanently.
PMCID: PMC2590663
PMID: 19079587 [PubMed - indexed for MEDLINE]
1: Med Hypotheses. 1999 Jul;53(1):6-16.
Modern diets and diseases: NO-zinc balance. Under Th1, zinc and nitrogen monoxide
(NO) collectively protect against viruses, AIDS, autoimmunity, diabetes,
allergies, asthma, infectious diseases, atherosclerosis and cancer.
Sprietsma JE.
Bennekom, The Netherlands.
Thanks to progress in zinc research, it is now possible to describe in more detail how zinc ions (Zn++) and nitrogen monoxide (NO), together with glutathione (GSH) and its oxidized form, GSSG, help to regulate immune responses to antigens. NO appears to be able to liberate Zn++ from metallothionein (MT), an intracellular storage molecule for metal ions such as zinc (Zn++) and copper (Cu++). Both Zn++ and Cu++ show a concentration-dependent inactivation of a protease essential for the proliferation of the AIDS virus HIV-1, while zinc can help prevent diabetes complications through its intracellular activation of the enzyme sorbitol dehydrogenase (SDH). A Zn++ deficiency can lead to a premature transition from efficient Th1-dependent cellular antiviral immune functions to Th2-dependent humoral immune functions. Deficiencies of Zn++, NO and/or GSH shift the Th1/Th2 balance towards Th2, as do deficiencies of any of the essential nutrients (ENs) - a group that includes methionine, cysteine, arginine, vitamins A, B, C and E, zinc and selenium (Se) - because these are necessary for the synthesis and maintenance of sufficient amounts of GSH, MT and NO. Via the Th1/Th2 balance, Zn++, NO, MT and GSH collectively determine the progress and outcome of many diseases. Disregulation of the Th1/Th2 balance is responsible for autoimmune disorders such as diabetes mellitus. Under Th2, levels of interleukin-4 (II-4), II-6, II-10, leukotriene B4 (LTB4) and prostaglandin E2(PGE2) are raised, while levels of II-2, Zn++, NO and other substances are lowered. This makes things easier for viruses like HIV-1 which multiply in Th2 cells but rarely, if ever, in Th1 cells. AIDS viruses (HIVs) enter immune cells with the aid of the CD4 cell surface receptor in combination with a number of co-receptors which include CCR3, CCR5 and CXCR4. Remarkably, the cell surface receptor for LTB4 (BLTR) also seems to act as a co-receptor for CD4, which helps HIVs to infect immune cells. The Th2 cytokine II-4 increases the number of CXCR4 and BLTR co-receptors, as a result of which, under Th2, the HIV strains that infect immune cells are precisely those that are best able to accelerate the AIDS disease process. The II-4 released under Th2 therefore not only promotes the production of more HIVs and the rate at which they infect immune cells, it also stimulates selection for the more virulent strains. Zn++ inhibit LTB4 production and numbers of LTB4 receptors (BLTRs) in a concentration-dependent way. Zn++ help cells to keep their LTB4 'doors' shut against the more virulent strains of HIV. Moreover, a sufficiency of Zn++ and NO prevents a shift of the Th1/Th2 balance towards Th2 and thereby slows the proliferation of HIV, which it also does by inactivating the HIV protease. Research makes it look likely that deficiencies of ENs such as zinc promote the proliferation of Th2 cells at the expense of Th1 cells. Zinc deficiency also promotes cancer. Under the influence of Th1 cells, zinc inhibits the growth of tumours by activating the endogenous tumour-suppressor endostatin, which inhibits angiogenesis. The modern Western diet, with its excess of refined products such as sugar, alcohol and fats, often contains, per calorie, a deficiency of ENs such as zinc, selenium and vitamins A, B, C and E, which results in disturbed immune functions, a shifted Th1/Th2 balance, chronic (viral) infections, obesity, atherosclerosis, autoimmunity, allergies and cancer. In view of this, an optimization of dietary composition would seem to give the best chance of beating (viral) epidemics and common (chronic) diseases at a realistic price.
PMID: 10499817 [PubMed - indexed for MEDLINE]
1: Virus Genes. 2004 Apr;28(3):319-31.
HIV-1 induced AIDS is an allergy and the allergen is the Shed gp120--a review,
hypothesis, and implications.
Becker Y.
Department of Molecular Virology, Faculty of Medicine, The Hebrew University of
Jerusalem, P.O. Box 12272, Jerusalem 91120, Israel. becker@med.huji.ac.il
The possibility that the induction of T helper 2 (Th2) cytokine synthesis and the gradual increase in interleukin 4 (IL-4) and IgE levels during HIV-1 infection are an allergic response to HIV-1 proteins was raised in the author's previous article [Becker, Virus Genes 28, 1-4, 2004]. The present review extends this hypothesis by citing experimental reports which indicate that HIV-1 shed gp120 virions share a striking resemblance with the allergens that bind to IgE molecules bound to Fc epsilon receptor I-positive (Fc epsilon RI) cells (mast cells, basophils, monocytes, and dendritic cells, DC) and then induce them to release and synthesize the IL-4 cytokine. In the earlier review, it was established that the IL-4 cytokine is responsible for the following processes: IgE synthesis by B cells and the inhibition of antiviral IgG synthesis; the inactivation of T helper 1 (Th1) cells; and the inhibition of the antiviral cytotoxic T cell (CTL) response. The binding of the shed gp120 to B cell-bound immunoglobulin (Ig) depletes these cells. Moreover, it was reported that the viral regulatory proteins Tat and Vpr also stimulate IL-4 release from basophils. The mode of action used by HIV-1 gp120 in the induction of IL-4 [Becker, Virus Genes 28, 1-14, 2004] revealed that the viral protein contains a superantigen (SAg) domain that is capable of binding to the V(H)3 domain of IgE and Ig; namely, the shed gp120 protein act as endogenous and environmental allergens that
bind to IgE molecules, which are bound to the Fc epsilon RI receptors on hematopoietic cells. Based on these findings, it is hypothesized that gp120 is an allergen. Consequently, it can be inferred that the active replication of HIV-1 in infected individuals constantly exposes the immune system to an increase in the allergen content until the host immunity is eventually compromised. These finding suggest that HIV-1 engage in a two-pronged attack of the human immune system: it infects Th2 cells, macrophages, and DCs and then replicates at these venues; and the shed gp120 cells cause an allergy. This allergic condition consequently prevents the induction of Th1 cells, cytokine synthesis, and antiviral CTLs that are needed to clear the infecting virus and thus devitalizes the antivirals that are used to treat the virus infection. It was hypothesized [Becker, Virus Genus 28, 1-14, 2004] that the HIV-1 induced allergy can be treated with IL-4 inhibitors or immune response modifiers. A treatment that employs both antivirals and anti-allergen drugs may very well defeat the AIDS syndrome. Another implication of the present hypothesis is the need to improve the viral antigen used for vaccinating healthy individuals against HIV-1 infection. It is thus suggested harmful domains be eliminated from the gp120.
PMID: 15266113 [PubMed - indexed for MEDLINE]
If this is true, there are many things which dampen Th2 and augment Th1 naturally, such as L-theanine, zinc, selenium, and things like citrus:
1: Mediators Inflamm. 2008;2008:496467. Epub 2008 Nov 30.
Citrus/Cydonia comp. can restore the immunological balance in seasonal allergic
rhinitis-related immunological parameters in vitro.
Baars EW, Savelkoul HF.
Department of Healthcare and Nutrition, Louis Bolk Instituut, 3972 LA Driebergen,
The Netherlands. e.baars@louisbolk.nl
In two in vitro studies, we examined the immunological (pathways of the) effects of Citrus/Cydonia comp. from, respectively, a healthy and an allergic donor; peripheral blood mononuclear cells (PBMCs) were isolated out of peripheral blood and analyzed in vitro after polyclonal stimulation of T-cells. The differentiation capacity and the influence with regard to Th1 (IFN-gamma) and Th2 (IL-5) cells were examined. Citrus/Cydonia comp. has a selective effect on the differentiation of T-cells by producing relatively more IL-10 than IL-12. By that, it also seems to have an effect on the induction of regulatory (IL-10 producing) T-cell subsets. It is in vitro capable of neutralizing (to some extent) the changes, characteristic to allergic rhinitis, with regard to the maturation, differentiation, and activity of the immune system. Thus, Citrus/Cydonia comp. can potentially restore the disturbed immune state of rhinitis patients, which essentially could be sufficient to make allergic
symptoms disappear permanently.
PMCID: PMC2590663
PMID: 19079587 [PubMed - indexed for MEDLINE]
1: Med Hypotheses. 1999 Jul;53(1):6-16.
Modern diets and diseases: NO-zinc balance. Under Th1, zinc and nitrogen monoxide
(NO) collectively protect against viruses, AIDS, autoimmunity, diabetes,
allergies, asthma, infectious diseases, atherosclerosis and cancer.
Sprietsma JE.
Bennekom, The Netherlands.
Thanks to progress in zinc research, it is now possible to describe in more detail how zinc ions (Zn++) and nitrogen monoxide (NO), together with glutathione (GSH) and its oxidized form, GSSG, help to regulate immune responses to antigens. NO appears to be able to liberate Zn++ from metallothionein (MT), an intracellular storage molecule for metal ions such as zinc (Zn++) and copper (Cu++). Both Zn++ and Cu++ show a concentration-dependent inactivation of a protease essential for the proliferation of the AIDS virus HIV-1, while zinc can help prevent diabetes complications through its intracellular activation of the enzyme sorbitol dehydrogenase (SDH). A Zn++ deficiency can lead to a premature transition from efficient Th1-dependent cellular antiviral immune functions to Th2-dependent humoral immune functions. Deficiencies of Zn++, NO and/or GSH shift the Th1/Th2 balance towards Th2, as do deficiencies of any of the essential nutrients (ENs) - a group that includes methionine, cysteine, arginine, vitamins A, B, C and E, zinc and selenium (Se) - because these are necessary for the synthesis and maintenance of sufficient amounts of GSH, MT and NO. Via the Th1/Th2 balance, Zn++, NO, MT and GSH collectively determine the progress and outcome of many diseases. Disregulation of the Th1/Th2 balance is responsible for autoimmune disorders such as diabetes mellitus. Under Th2, levels of interleukin-4 (II-4), II-6, II-10, leukotriene B4 (LTB4) and prostaglandin E2(PGE2) are raised, while levels of II-2, Zn++, NO and other substances are lowered. This makes things easier for viruses like HIV-1 which multiply in Th2 cells but rarely, if ever, in Th1 cells. AIDS viruses (HIVs) enter immune cells with the aid of the CD4 cell surface receptor in combination with a number of co-receptors which include CCR3, CCR5 and CXCR4. Remarkably, the cell surface receptor for LTB4 (BLTR) also seems to act as a co-receptor for CD4, which helps HIVs to infect immune cells. The Th2 cytokine II-4 increases the number of CXCR4 and BLTR co-receptors, as a result of which, under Th2, the HIV strains that infect immune cells are precisely those that are best able to accelerate the AIDS disease process. The II-4 released under Th2 therefore not only promotes the production of more HIVs and the rate at which they infect immune cells, it also stimulates selection for the more virulent strains. Zn++ inhibit LTB4 production and numbers of LTB4 receptors (BLTRs) in a concentration-dependent way. Zn++ help cells to keep their LTB4 'doors' shut against the more virulent strains of HIV. Moreover, a sufficiency of Zn++ and NO prevents a shift of the Th1/Th2 balance towards Th2 and thereby slows the proliferation of HIV, which it also does by inactivating the HIV protease. Research makes it look likely that deficiencies of ENs such as zinc promote the proliferation of Th2 cells at the expense of Th1 cells. Zinc deficiency also promotes cancer. Under the influence of Th1 cells, zinc inhibits the growth of tumours by activating the endogenous tumour-suppressor endostatin, which inhibits angiogenesis. The modern Western diet, with its excess of refined products such as sugar, alcohol and fats, often contains, per calorie, a deficiency of ENs such as zinc, selenium and vitamins A, B, C and E, which results in disturbed immune functions, a shifted Th1/Th2 balance, chronic (viral) infections, obesity, atherosclerosis, autoimmunity, allergies and cancer. In view of this, an optimization of dietary composition would seem to give the best chance of beating (viral) epidemics and common (chronic) diseases at a realistic price.
PMID: 10499817 [PubMed - indexed for MEDLINE]
The Tragedy of Trivializing Natural Medicine Combined with Ignorance in HIV-AIDS
I was at the Stanford 10 year reunion, and I had someone come up to me and ask if I was going to prescribe beet-root, olive, lemon, and garlic to them.
The answer is a resounding yes, but only in the proper preparation, dosing, and indication. The idea that a salad or glass of veggie juice is going to help you in severe disease is, of course, absurd. So no, I am not going to suggest you eat a salad to cure your disease, which in this case may be mental. It turns out that a trained biologist, not a politician, or a trust-fund daughter with no background in biology would be able to see that each one of those have anti-viral molecules within them. If you were to extract and concentrate these, you would have an effective anti-viral medication. It really is sad that wealth blinds people from the truth.
BEET ROOT:
1: Cancer Lett. 1996 Feb 27;100(1-2):211-4.
Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract.
Kapadia GJ, Tokuda H, Konoshima T, Nishino H.
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical
Sciences, Howard University, Washington, DC 20059, USA.
The in vitro inhibitory effect of Beta vulgaris (beet) root extract on Epstein-Barr virus early antigen (EBV-EA) induction using Raji cells revealed a high order of activity compared to capsanthin, cranberry, red onion skin and short and long red bell peppers. An in vivo anti-tumor promoting activity evaluation against the mice skin and lung bioassays also revealed a significant tumor inhibitory effect. The combined findings suggest that beetroot ingestion can be one of the useful means to prevent cancer.
OLIVE:
PMID: 8620443 [PubMed - indexed for MEDLINE]
1: FEBS Lett. 2007 Jun 12;581(14):2737-42. Epub 2007 May 21.
Computational study of bindings of olive leaf extract (OLE) to HIV-1 fusion
protein gp41.
Bao J, Zhang DW, Zhang JZ, Huang PL, Huang PL, Lee-Huang S.
Department of Chemistry, New York University, New York, NY 10003, USA.
Recent experimental study found that OLE (olive leaf extract) has anti-HIV activity by blocking the HIV virus entry to host cells [Lee-Huang, S., Zhang, L., Huang, P.L., Chang, Y. and Huang, P.L. (2003) Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment. Biochem. Biophys. Res. Commun. 307, 1029; Lee-Huang, S., Huang, P.L., Zhang, D., Lee, J.W., Bao, J., Sun, Y., Chang, Y.-Tae, Zhang, J.Z.H. and Huang, P.L. (2007) Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol. Biochem. Biophys. Res. Commun. 354, 872-878, 879-884]. As part of a joint experimental and theoretical effort, we report here computational study to help identify and characterize the binding complexes of several main compounds of OLE (olive leaf extract) to HIV-1 envelop protein gp41. A number of possible binding modes are found by docking oleuropein and its metabolites, aglycone, elenolic acid and hydroxytyrosol, onto the hydrophobic pocket on gp41. Detailed OLE-gp41 binding interactions and free energies of binding are obtained through molecular dynamics simulation and MM-PBSA calculation. Specific molecular interactions in our predicted OLE/gp41 complexes are identified and hydroxytyrosol is identified to be the main moiety for binding to gp41. This computational study complements the corresponding experimental investigation and helps establish a good starting point for further refinement of OLE-based gp41 inhibitors.
LEMON:
PMID: 17537437 [PubMed - indexed for MEDLINE]
1: J Biol Chem. 2004 Sep 3;279(36):37349-59. Epub 2004 Jun 24.
Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway.
Sancho R, Márquez N, Gómez-Gonzalo M, Calzado MA, Bettoni G, Coiras MT, Alcamí J,
López-Cabrera M, Appendino G, Muñoz E.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de
Córdoba, Facultad de Medicina, Avda. de Menendez Pidal s/n, 14004 Córdoba, Spain.
Coumarins and structurally related compounds have been recently shown to present anti-human immunodeficiency virus, type 1 (HIV-1) activity. Among them, the dietary furanocoumarin imperatorin is present in citrus fruits, in culinary herbs, and in some medicinal plants. In this study we report that imperatorin inhibits either vesicular stomatitis virus-pseudotyped or gp160-enveloped recombinant HIV-1 infection in several T cell lines and in HeLa cells. These recombinant viruses express luciferase as a marker of viral replication. Imperatorin did not inhibit the reverse transcription nor the integration steps in the viral cell cycle. Using several 5' long terminal repeat-HIV-1 constructs where critical response elements were either deleted or mutated, we found that the transcription factor Sp1 is critical for the inhibitory activity of imperatorin induced by both phorbol 12-myristate 13-acetate and HIV-1 Tat. Moreover in transient transfections imperatorin specifically inhibited phorbol 12-myristate 13-acetate-induced transcriptional activity of the Gal4-Sp1 fusion protein. Since Sp1 is also implicated in cell cycle progression we further studied the effect of imperatorin on cyclin D1 gene transcription and protein expression and in HeLa cell cycle progression. W e found that imperatorin strongly inhibited cyclin D1 expression and arrested the cells at the G(1) phase of the cell cycle. These results highlight the potential of Sp1 transcription factor as a target for natural anti-HIV-1 compounds such as furanocoumarins that might have a potential therapeutic role in the management of AIDS.
GARLIC:
PMID: 15218031 [PubMed - indexed for MEDLINE]
1: Vestn Ross Akad Med Nauk. 1992;(11-12):6-10.
[The ajoene blockade of integrin-dependent processes in an HIV-infected cell
system]
[Article in ]
Tatarintsev AV, Vrzhets PV, Ershov DE, Shchegolev AA, Turgiev AS, Karamov EV,
Kornilaeva GV, Makarova TV, Fedorov NA, Varfolomeev SD.
Ajoene, (E,Z)-4,5,9-trithiadodeca-1,6,11-triene-9-oxide, isolated from extracts of garlic (Allium sativum) has been previously shown to inhibit platelet aggregation by inactivating allosterically the platelet integrin, GP IIb/IIIa. The structural and functional similarity of integrins led the authors to suggest that ajoene may also inhibit adhesive interactions and fusion of leukocytes. Synthetic stereoisomers of ajoene synthesized by the authors exhibited equal antiaggregatory activities (IC100 approximately 50 microM for platelets; IC100 approximately 10 microM for fMLP-stimulated neutrophils). Racemic ajoene inhibited the fusion of H9 cells with HIV-infected H9:RF cells (IC50 approximately 45 microM; 16 h of incubation) and also exhibited a degree of antiviral activity (IC50 approximately 5 microM as assessed by inhibition of HIV-1/CEM/Lav 1 Bru replication in CEM13 cells; m. o. i. 0.1; 72 h). A
considerable increase in the latter became evident when the compound was administered in aliquots of 50 microM per 12 h of incubation (inhibition by 30%; total concentration 0.25 microM; 72 h).(ABSTRACT TRUNCATED AT 250 WORDS)
PMID: 1284227 [PubMed - indexed for MEDLINE]
It's proof that an ivy league education doesn't do away with bias, bigotry, and superiority complexes that can blind you to the truth. When there is a real, good, affordable cure, then maybe you can ridicule these sources of medicine, which were the origins of modern medicine anyways. Until then, leave the research alone and stick to whatever you took classes for.
The answer is a resounding yes, but only in the proper preparation, dosing, and indication. The idea that a salad or glass of veggie juice is going to help you in severe disease is, of course, absurd. So no, I am not going to suggest you eat a salad to cure your disease, which in this case may be mental. It turns out that a trained biologist, not a politician, or a trust-fund daughter with no background in biology would be able to see that each one of those have anti-viral molecules within them. If you were to extract and concentrate these, you would have an effective anti-viral medication. It really is sad that wealth blinds people from the truth.
BEET ROOT:
1: Cancer Lett. 1996 Feb 27;100(1-2):211-4.
Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract.
Kapadia GJ, Tokuda H, Konoshima T, Nishino H.
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical
Sciences, Howard University, Washington, DC 20059, USA.
The in vitro inhibitory effect of Beta vulgaris (beet) root extract on Epstein-Barr virus early antigen (EBV-EA) induction using Raji cells revealed a high order of activity compared to capsanthin, cranberry, red onion skin and short and long red bell peppers. An in vivo anti-tumor promoting activity evaluation against the mice skin and lung bioassays also revealed a significant tumor inhibitory effect. The combined findings suggest that beetroot ingestion can be one of the useful means to prevent cancer.
OLIVE:
PMID: 8620443 [PubMed - indexed for MEDLINE]
1: FEBS Lett. 2007 Jun 12;581(14):2737-42. Epub 2007 May 21.
Computational study of bindings of olive leaf extract (OLE) to HIV-1 fusion
protein gp41.
Bao J, Zhang DW, Zhang JZ, Huang PL, Huang PL, Lee-Huang S.
Department of Chemistry, New York University, New York, NY 10003, USA.
Recent experimental study found that OLE (olive leaf extract) has anti-HIV activity by blocking the HIV virus entry to host cells [Lee-Huang, S., Zhang, L., Huang, P.L., Chang, Y. and Huang, P.L. (2003) Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment. Biochem. Biophys. Res. Commun. 307, 1029; Lee-Huang, S., Huang, P.L., Zhang, D., Lee, J.W., Bao, J., Sun, Y., Chang, Y.-Tae, Zhang, J.Z.H. and Huang, P.L. (2007) Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol. Biochem. Biophys. Res. Commun. 354, 872-878, 879-884]. As part of a joint experimental and theoretical effort, we report here computational study to help identify and characterize the binding complexes of several main compounds of OLE (olive leaf extract) to HIV-1 envelop protein gp41. A number of possible binding modes are found by docking oleuropein and its metabolites, aglycone, elenolic acid and hydroxytyrosol, onto the hydrophobic pocket on gp41. Detailed OLE-gp41 binding interactions and free energies of binding are obtained through molecular dynamics simulation and MM-PBSA calculation. Specific molecular interactions in our predicted OLE/gp41 complexes are identified and hydroxytyrosol is identified to be the main moiety for binding to gp41. This computational study complements the corresponding experimental investigation and helps establish a good starting point for further refinement of OLE-based gp41 inhibitors.
LEMON:
PMID: 17537437 [PubMed - indexed for MEDLINE]
1: J Biol Chem. 2004 Sep 3;279(36):37349-59. Epub 2004 Jun 24.
Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway.
Sancho R, Márquez N, Gómez-Gonzalo M, Calzado MA, Bettoni G, Coiras MT, Alcamí J,
López-Cabrera M, Appendino G, Muñoz E.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de
Córdoba, Facultad de Medicina, Avda. de Menendez Pidal s/n, 14004 Córdoba, Spain.
Coumarins and structurally related compounds have been recently shown to present anti-human immunodeficiency virus, type 1 (HIV-1) activity. Among them, the dietary furanocoumarin imperatorin is present in citrus fruits, in culinary herbs, and in some medicinal plants. In this study we report that imperatorin inhibits either vesicular stomatitis virus-pseudotyped or gp160-enveloped recombinant HIV-1 infection in several T cell lines and in HeLa cells. These recombinant viruses express luciferase as a marker of viral replication. Imperatorin did not inhibit the reverse transcription nor the integration steps in the viral cell cycle. Using several 5' long terminal repeat-HIV-1 constructs where critical response elements were either deleted or mutated, we found that the transcription factor Sp1 is critical for the inhibitory activity of imperatorin induced by both phorbol 12-myristate 13-acetate and HIV-1 Tat. Moreover in transient transfections imperatorin specifically inhibited phorbol 12-myristate 13-acetate-induced transcriptional activity of the Gal4-Sp1 fusion protein. Since Sp1 is also implicated in cell cycle progression we further studied the effect of imperatorin on cyclin D1 gene transcription and protein expression and in HeLa cell cycle progression. W e found that imperatorin strongly inhibited cyclin D1 expression and arrested the cells at the G(1) phase of the cell cycle. These results highlight the potential of Sp1 transcription factor as a target for natural anti-HIV-1 compounds such as furanocoumarins that might have a potential therapeutic role in the management of AIDS.
GARLIC:
PMID: 15218031 [PubMed - indexed for MEDLINE]
1: Vestn Ross Akad Med Nauk. 1992;(11-12):6-10.
[The ajoene blockade of integrin-dependent processes in an HIV-infected cell
system]
[Article in ]
Tatarintsev AV, Vrzhets PV, Ershov DE, Shchegolev AA, Turgiev AS, Karamov EV,
Kornilaeva GV, Makarova TV, Fedorov NA, Varfolomeev SD.
Ajoene, (E,Z)-4,5,9-trithiadodeca-1,6,11-triene-9-oxide, isolated from extracts of garlic (Allium sativum) has been previously shown to inhibit platelet aggregation by inactivating allosterically the platelet integrin, GP IIb/IIIa. The structural and functional similarity of integrins led the authors to suggest that ajoene may also inhibit adhesive interactions and fusion of leukocytes. Synthetic stereoisomers of ajoene synthesized by the authors exhibited equal antiaggregatory activities (IC100 approximately 50 microM for platelets; IC100 approximately 10 microM for fMLP-stimulated neutrophils). Racemic ajoene inhibited the fusion of H9 cells with HIV-infected H9:RF cells (IC50 approximately 45 microM; 16 h of incubation) and also exhibited a degree of antiviral activity (IC50 approximately 5 microM as assessed by inhibition of HIV-1/CEM/Lav 1 Bru replication in CEM13 cells; m. o. i. 0.1; 72 h). A
considerable increase in the latter became evident when the compound was administered in aliquots of 50 microM per 12 h of incubation (inhibition by 30%; total concentration 0.25 microM; 72 h).(ABSTRACT TRUNCATED AT 250 WORDS)
PMID: 1284227 [PubMed - indexed for MEDLINE]
It's proof that an ivy league education doesn't do away with bias, bigotry, and superiority complexes that can blind you to the truth. When there is a real, good, affordable cure, then maybe you can ridicule these sources of medicine, which were the origins of modern medicine anyways. Until then, leave the research alone and stick to whatever you took classes for.
Monday, June 8, 2009
Cheerios: Drugs for breakfast?
Cheerios: Drugs for breakfast?
Shared via AddThis
Clearly the FDA is corrupt and evil. Oat fiber cereal (proven to lower cholesterol) a drug? Ridiculous.
Shared via AddThis
Clearly the FDA is corrupt and evil. Oat fiber cereal (proven to lower cholesterol) a drug? Ridiculous.
Sunday, June 7, 2009
Please do your part to preserve your freedom and liberty in preserving your health naturally:
Defend DSHEA from going down.
There will be countless arguments by the pill pusher-money cabal to take this down. Then, all your neighborhood grocery stores, drug stores, your Whole Foods, Trader Joes, Aldi(s), and convenience stores will be empty and barren of nature's pharmacy. The tyranny of the greedy will have made your shelves barren of natural medicine, and will force you to pay and pay and pay needlessly for drugs that enrich them, may not work, or may even cause worse problems. This is not freedom, it is slavery.
Please do your part to defend your own freedom.
There will be countless arguments by the pill pusher-money cabal to take this down. Then, all your neighborhood grocery stores, drug stores, your Whole Foods, Trader Joes, Aldi(s), and convenience stores will be empty and barren of nature's pharmacy. The tyranny of the greedy will have made your shelves barren of natural medicine, and will force you to pay and pay and pay needlessly for drugs that enrich them, may not work, or may even cause worse problems. This is not freedom, it is slavery.
Please do your part to defend your own freedom.
Enough already with "alternative medicine" and "herbal remedies" labels
Plant medicines were the source of all synthetic, pilled medicines today.
Everything is molecular in nature, so it is no use to call an herb less medicinal than a "small molecule," because both are the same. Herbs contain small molecules, and small molecules exist in "herbs."
Pharmaceutical media tries to minimalize and trivialize "herbal medicine" by trying to coin it as some kind of culinary problem. It isn't. "Herbal medicine" has some very effective medicines, some as powerful if not better than conventional pharmaceuticals, and for far cheaper.
On the other hand, we must be wary of unscrupulous herbal medicine dealers who sell things that are tainted with lead, mercurcy, microbes, and other taints. Those who are dogmatic by either polemic are very suspect in their character and may be more interested in their egos or their position in a hierarchy than actually helping people.
To quote a salesman of the pharmaceutical industry, "We are not interested in curing anyone. We are a business." When I hear anyone say something to the tune of "It's just business," they are proclaiming publicly that they have no soul other than that they have sold in a Faustian deal with the devil. They proclaim that they choose to be venal and perfidious, as opposed to being honest and naked in their dealings with their fellow human beings.
As far as your health goes, I would never be anything less than brutally honest and unbiased, ever looking out for you in an impartial way without judgement. From this standpoint, I can say that it is definitely unfavorable for DSHEA to be voted down by any government official who is conspiring with Pharma business.
Everything is molecular in nature, so it is no use to call an herb less medicinal than a "small molecule," because both are the same. Herbs contain small molecules, and small molecules exist in "herbs."
Pharmaceutical media tries to minimalize and trivialize "herbal medicine" by trying to coin it as some kind of culinary problem. It isn't. "Herbal medicine" has some very effective medicines, some as powerful if not better than conventional pharmaceuticals, and for far cheaper.
On the other hand, we must be wary of unscrupulous herbal medicine dealers who sell things that are tainted with lead, mercurcy, microbes, and other taints. Those who are dogmatic by either polemic are very suspect in their character and may be more interested in their egos or their position in a hierarchy than actually helping people.
To quote a salesman of the pharmaceutical industry, "We are not interested in curing anyone. We are a business." When I hear anyone say something to the tune of "It's just business," they are proclaiming publicly that they have no soul other than that they have sold in a Faustian deal with the devil. They proclaim that they choose to be venal and perfidious, as opposed to being honest and naked in their dealings with their fellow human beings.
As far as your health goes, I would never be anything less than brutally honest and unbiased, ever looking out for you in an impartial way without judgement. From this standpoint, I can say that it is definitely unfavorable for DSHEA to be voted down by any government official who is conspiring with Pharma business.
Wednesday, June 3, 2009
Some work I did on Mesenchymal Stem Cell Therapy on the Infarcted Myocardium
"Myocardial survival signaling in response to stem cell transplantation."
Osiris Therapeutics had something going on in this respect. We're talking "too late," and "too far gone," not prevention.
Osiris Therapeutics had something going on in this respect. We're talking "too late," and "too far gone," not prevention.
Sunday, May 31, 2009
Why a hot cuppa is better for you than you think:
Sure, there is the addictive caffeine, and the tea stains, but imagine that caffeine megalomania of coffee toned down by the ingredients of L-theanine, a psychoactive and immunoactive ingredient. So when you see your workers or colleagues drinking tea, it is so that they are more efficient, focused, and mentally stable. I once worked with a high-strung man who claimed that all I did was sit around and drink tea. Well dude, if it wasn't for me drinking tea all day, making the molecular lab from scratch thanks to the good doctor, you wouldn't be working there to complain about everything.
Black tea and L-theanine.
Black tea and L-theanine.
Thursday, May 7, 2009
Anti-proliferative effect of ascorbic acid
This is a fascinating paper. Of course, one should read it and see the methods and dosage.
Belin et. al
Belin et. al
Tuesday, April 7, 2009
Hyperhomocysteinemia, Hyperglycemia, Hypertension, Oxidative Stress, and Inflammation = Atherosclerosis
Given that pathological changes to the liver cause a reduction in plasma LDL and Lp(a), it doesn't necessarily follow that cholesterol is a causal factor in pathological conditions. Especially if an individual has normal cholesterol metabolism, and isn't shoveling in excessive canisters of saturated fats (paraffins/waxes) and hydrogenated oils (gasoline) into their mouths, plasma cholesterol (HDL, LDL, ILDL, VLDLDL, Lp(a) are responses to other conditions. Something that is often misunderstood is that there are many kinds of fat, only one cholesterol, free cholesterol, esterified cholesterol, and several lipoproteins that include cholesterol. Cholesterol on its own is not water soluble. Cholesterol can only travel through the blood if part of a protein or polar lipid shuttle, such as that constituted by lipoproteins. LDL then is NOT cholesterol, but ApoB protein and cholesterol which serves to shuttle cholesterol through the blood to where it is supposed to go. These proteins, ApoA, ApoB, ApoE, ApoJ, Apo(a), etc. are not just randomly secreted by the liver. They are made for a purpose under the control of a homeostat protein. Just as rusted (oxidized) or rotten food can poison someone, so can rusted or rotten lipoprotein (oxidized LDL, ox-LDL, ox-phospholipid, nitrated, glycated, chlorinated, denatured lipid/lipoprotein) poison the repair system of the artery. This poison dump causes a local immune system reaction to attempt to clear out the junk yard. Yet, each soldier (white blood cell) that comes to the site gets poisoned and dies there in the graveyard (foam cell lesion that becomes necrotic core). This graveyard then gets bigger and bigger, until it is finally the atherosclerotic lesion.
It is true that it is associated with pathological conditions, and that hereditary hypercholesterolemia and build up syndromes cause disease. It is also true that some individuals have a genetic predisposition to higher Lp(a) or LDL levels. Yet, it is also true that natural and ubiquitous hormones such as testosterone and naturally produced and occurring antioxidants such as CoQ(10) can dramatically lower this "harmful" cholesterol.
So then, without a person inhaling several burgers, a grocery bag of trans-fat fries, and an entire gallon of whole milk ice-cream a day, what is it?
It is true that it is associated with pathological conditions, and that hereditary hypercholesterolemia and build up syndromes cause disease. It is also true that some individuals have a genetic predisposition to higher Lp(a) or LDL levels. Yet, it is also true that natural and ubiquitous hormones such as testosterone and naturally produced and occurring antioxidants such as CoQ(10) can dramatically lower this "harmful" cholesterol.
So then, without a person inhaling several burgers, a grocery bag of trans-fat fries, and an entire gallon of whole milk ice-cream a day, what is it?
The Worldwide Model for Cardiovascular Medicine:
1) The ApoE KO mouse.
2) The LDL receptor KO mouse.
(sometimes they use salt hypertensive or STZ diabetic models)
None of these have apo(a) as humans do, and all create ascorbate within their own livers which humans don't do. Another thing to keep in mind is that mice eat 1/4 their own weight ( ! ) in food a day. For a 150 pound human, that is nearly 38 pounds of food a day. This doesn't reduce the validity of the model, but people generally ignore some profound differences between mouse and man. This mouse model is the main pillar of all of cardiovascular medicine for humans.
2) The LDL receptor KO mouse.
(sometimes they use salt hypertensive or STZ diabetic models)
None of these have apo(a) as humans do, and all create ascorbate within their own livers which humans don't do. Another thing to keep in mind is that mice eat 1/4 their own weight ( ! ) in food a day. For a 150 pound human, that is nearly 38 pounds of food a day. This doesn't reduce the validity of the model, but people generally ignore some profound differences between mouse and man. This mouse model is the main pillar of all of cardiovascular medicine for humans.
The Comedy of Academic Journals:
I have been published in various places already, but here is my recent experience in the field of cardiovascular medicine:
There is no cure for Aortic Aneurysm. No surgical intervention works very long, in fact this is what the famous Dr. DeBakey (DeBaghi) died of.
My first reviewer had some valid requests, but we can't do it because we have other things to do and other people have already proven what they ask for. They also ask to prove a parameter through a litmus test, when the evidence for it is right in front of them in another form.
The second reviewer obviously didn't even read the paper. They claim that I claim that the plaques resolve themselves, which is never stated anywhere within the paper. They are either asleep at the wheel or yet another pawn of scientific disinformation. The other absurd thing they request is "citations" for a novel find.
Oh well. Dr. DeBakey is turning in his grave. If I had to, I would just put the paper online and claim, "All of it is true, but there are no peer reviewers."
Here it is, and I am the first to state it ever in the world: In Mice, Aortic Dissections heal themselves often, but they do not in humans. Whoever claims it again basically owes me credit for the assertion of the whole chain of discovery. ha!
As history has shown, the ancient pillars of science are not infallible, and no human is infallible in their assertions. The gloss or prestige of a journal is only so important as to have power, but there are plenty of retractions and corrections in high profile science.
There is no cure for Aortic Aneurysm. No surgical intervention works very long, in fact this is what the famous Dr. DeBakey (DeBaghi) died of.
My first reviewer had some valid requests, but we can't do it because we have other things to do and other people have already proven what they ask for. They also ask to prove a parameter through a litmus test, when the evidence for it is right in front of them in another form.
The second reviewer obviously didn't even read the paper. They claim that I claim that the plaques resolve themselves, which is never stated anywhere within the paper. They are either asleep at the wheel or yet another pawn of scientific disinformation. The other absurd thing they request is "citations" for a novel find.
Oh well. Dr. DeBakey is turning in his grave. If I had to, I would just put the paper online and claim, "All of it is true, but there are no peer reviewers."
Here it is, and I am the first to state it ever in the world: In Mice, Aortic Dissections heal themselves often, but they do not in humans. Whoever claims it again basically owes me credit for the assertion of the whole chain of discovery. ha!
As history has shown, the ancient pillars of science are not infallible, and no human is infallible in their assertions. The gloss or prestige of a journal is only so important as to have power, but there are plenty of retractions and corrections in high profile science.
Wednesday, March 25, 2009
Vitamin C as a Cancer Target (From Wikipedia)
A biologist knows what a LOF mutation is and induces these to study what a gene function is. In the case of natural mutants of the VHF gene, these patients are very prone to cancer disease partially by constitutive activation of HIF. By adding elements (of which vitamin C is one), this process could be reversed:
"Treatment
Suggested targets for VHL-related cancers include targets of the HIF pathway, such as VEGF. Two inhibitors of VEGF sorafenib and sunitinib have recently been approved by the FDA [6]. The mTOR inhibitor rapamycin may also be an option [9]. Bevacizumab, a monoclonal antibody targeting VEGF, is one medication currently undergoing clinical trials
Since iron, 2-oxoglutarate and oxygen are necessary for the inactivation of HIF, it has been theorized that a lack of these cofactors could reduce the ability of hydroxlases in inactivating HIF. A recent study has shown that in cells with a high activation of HIF even in oxygenated environments was reversed by supplying the cells with ascorbate [10]. Thus, Vitamin C may be a potential treatment for HIF induced tumors." (as of 3/25/09) reference 10 being:
^ Knowles HJ, Raval RR, Harris AL, Ratcliffe, PJ. (2003). "Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells.". Cancer research 63: 1764–8.
Here is the Wikipedia link showing the value of vitamin C as a therapeutic against cancer: http://en.wikipedia.org/wiki/Von_Hippel-Lindau_tumor_suppressor link
"Treatment
Suggested targets for VHL-related cancers include targets of the HIF pathway, such as VEGF. Two inhibitors of VEGF sorafenib and sunitinib have recently been approved by the FDA [6]. The mTOR inhibitor rapamycin may also be an option [9]. Bevacizumab, a monoclonal antibody targeting VEGF, is one medication currently undergoing clinical trials
Since iron, 2-oxoglutarate and oxygen are necessary for the inactivation of HIF, it has been theorized that a lack of these cofactors could reduce the ability of hydroxlases in inactivating HIF. A recent study has shown that in cells with a high activation of HIF even in oxygenated environments was reversed by supplying the cells with ascorbate [10]. Thus, Vitamin C may be a potential treatment for HIF induced tumors." (as of 3/25/09) reference 10 being:
^ Knowles HJ, Raval RR, Harris AL, Ratcliffe, PJ. (2003). "Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells.". Cancer research 63: 1764–8.
Here is the Wikipedia link showing the value of vitamin C as a therapeutic against cancer: http://en.wikipedia.org/wiki/Von_Hippel-Lindau_tumor_suppressor link
Tuesday, March 24, 2009
The Warburg Effect
The Warburg Effect, widely recognized by worldwide oncology as the way that human tumors generate their sustenance, is tied into the activation of HIF1-a and vice versa.
It is somewhat of a chicken or egg question of whether anoxia forced aerobic glycolysis or whether carcinogenesis turned on aerobic/anaerobic glycolysis.
This much is true - that HIF-1a is turned on by this process, in effect making cancerous cells immune to the normal genetic programs that destroy mutated and tumorigenic cells.
Vitamin C at physiological levels in fact disables HIF-1a profoundly, thereby inhibiting carcinogenesis before the fact or after the fact.
Reduced Ascorbic Acid is the key to unlocking the nexus between Von Hippel-Lindau Factor (VHF), HIF (hypoxia induced factor), apoptosis, and the cancer disease.
It is somewhat of a chicken or egg question of whether anoxia forced aerobic glycolysis or whether carcinogenesis turned on aerobic/anaerobic glycolysis.
This much is true - that HIF-1a is turned on by this process, in effect making cancerous cells immune to the normal genetic programs that destroy mutated and tumorigenic cells.
Vitamin C at physiological levels in fact disables HIF-1a profoundly, thereby inhibiting carcinogenesis before the fact or after the fact.
Reduced Ascorbic Acid is the key to unlocking the nexus between Von Hippel-Lindau Factor (VHF), HIF (hypoxia induced factor), apoptosis, and the cancer disease.
Saturday, March 21, 2009
Thursday, March 19, 2009
This is a joke right? America BANS gardening and organic farms????
That's ridiculous, evil, and very un-American. Obviously, this is just a joke, because if it were true, that means that evil Nazis have taken over USA and American Agriculture.
Banning Your Backyard?!?
What the heck does this convoluted law really mean?? Why does Monsanto, whose GMO are banned and frowned upon by all of Europe have something to do with this?
Must be a joke.
Banning Your Backyard?!?
What the heck does this convoluted law really mean?? Why does Monsanto, whose GMO are banned and frowned upon by all of Europe have something to do with this?
Must be a joke.
Wednesday, March 11, 2009
Don't Worry Prince Charles, Artichoke and Dandelion are Proven Detoxifiers
Prince Charles Detox Tincture
Artichoke is known to increase superoxide dismutase enzymes, the dandelion helps the kidneys in a diuretic action. Both assist the liver, which is the single most important organ in detoxification in tandem to the kidneys.
The critics shall step down.
Bile assistance
Assistance against gallstone
Antioxidant effect
and on and on
Artichoke is known to increase superoxide dismutase enzymes, the dandelion helps the kidneys in a diuretic action. Both assist the liver, which is the single most important organ in detoxification in tandem to the kidneys.
The critics shall step down.
Bile assistance
Assistance against gallstone
Antioxidant effect
and on and on
Sunday, March 8, 2009
Sunday, March 1, 2009
Cytokine reactions of the liver with Lp(a)
In chronic, low-level inflammation, there is more Lp(a) generated. In the case of severe burn trauma, Lp(a) is a negatively regulated acute phase reactant. It may be that the normal system is overriden or that it serves a useful purpose to have more proteolysis in this circumstance.
Here is the paper out of Parke-Davis/Warner Lambert
Here is the paper out of Parke-Davis/Warner Lambert
The NIH studies on ascorbic acid selective toxicity to cancer
(Mark Levine's work):
PNAS 2007 paper
PNAS 2008 in vivo work
Of course, this is one of several mechanisms by which it works. So there is scientific basis and demonstration across the board from the tube to the human for the claims on high dose vitamin C.
Obviously, this doesn't end basic research or anything in the fields of immunology, devbio, and regenerative medicine that seem to be making leaps and bounds. It does go to show that there are real foundations for these claims. It is a misfortune that people use health and science as political or emotional gambits of any kind, in any kind of polemic.
PNAS 2007 paper
PNAS 2008 in vivo work
Of course, this is one of several mechanisms by which it works. So there is scientific basis and demonstration across the board from the tube to the human for the claims on high dose vitamin C.
Obviously, this doesn't end basic research or anything in the fields of immunology, devbio, and regenerative medicine that seem to be making leaps and bounds. It does go to show that there are real foundations for these claims. It is a misfortune that people use health and science as political or emotional gambits of any kind, in any kind of polemic.
Subscribe to:
Posts (Atom)